NICE — Íàöèîíàëüíûé èíñòèòóò çäîðîâüÿ è êëèíè÷åñêîãî ñîâåðøåíñòâîâàíèÿ (êà÷åñòâà ìåäèöèíñêîé ïîìîùè) Âåëèêîáðèòàíèè (National Institute for Health and Clinical Excellence)
NK — åñòåñòâåííûå êëåòêè-êèëëåðû (natural killer)
NMDA — N-ìåòèë-D-àñïàðòàò (N-methyl-D-aspartate)
NMDA — N-ìåòèë-D-àñïàðòàòíûå ðåöåïòîðû
NNT — ÷èñëî áîëüíûõ, êîòîðûõ íåîáõîäèìî ïðîëå÷èòü, ÷òîáû äîñòè÷ü êàêîãî-òî óêàçàííîãî ýôôåêòà (Number Need to Treatment)
OR — îòíîøåíèå øàíñîâ (odds ratio)
paCO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà â àðòåðèàëüíîé êðîâè
PALS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè (Pediatric Advanced Life Support)
PANDAS — àóòîèììóííîå íåéðîïñèõèàòðè÷åñêîå ðàññòðîéñòâî â äåòñêîì âîçðàñòå, àññîöèèðîâàííîå ñî ñòðåïòîêîêêîâîé èíôåêöèåé (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
 õîäå ïîäãîòîâêè ñòàòåé ïî äåòñêîé ýíäîêðèíîëîãèè â ïåäèàòðèè äëÿ ïîëüçîâàòåëåé ñàéòà ÌåäÓíèâåð èñïîëüçîâàíû òðóäû ñëåäóþùèõ àâòîðîâ:
Alatzoglou KS, Dattani MT: Genetic forms of hypopituitarism and their manifestation in the neonatal period, Early Hum Dev 85:705–712, 2009.
Allen DB, Cuttler L: Short stature in children–challenges and choices, N Engl J Med 368(13):1220–1228, 2013.
Dezaki K: Ghrelin function in insulin release and glucose metabolism, Endocr Dev 25:135–143, 2013.
Kageyama H, Takenoya F, Shiba K, et al: Neuronal circuits involving ghrelin in the hypothalamus-mediated regulation of feeding, Neuropeptides 44:133–138, 2010.
Lawson EA, Holsen LM, Santin M: Oxytocin secretion is associated with severity of disordered eating psychopathology and insular cortex hypoactivation in anorexia nervosa, J Clin Endocrinol Metab 97:E1898–E1908, 2012.
Lee HJ, Macbeth AH, Pagani JH, et al: Oxytocin: the great facilitator of life, Prog Neurobiol 88:127–151, 2009.
Lem AJ, de Rijke YB, van Toor H, et al: Serum thyroid hormone levels in healthy children from birth to adulthood and in short children born small for gestational age, J Clin Endocrinol Metab 97:3170–3178, 2012.
Thompson IR, Ciccone NA, Xu S, et al: GnRH pulse frequency-dependent stimulationof FSH ?transcription is mediated via activation of PKA and CREB, Mol Endocrinol 27(4):606–618, 2013.
van Vught AJ, Nieuwenhuizen AG, Gerver WJ, et al: Pharmacological and physiological growth hormone stimulation tests to predict successful GH therapy in children, J Pediatr Endocrinol Metab 22:679–694, 2009
Alatzoglou KS, Dattani MT: Genetic forms of hypopituitarism and their manifestation in the neonatal period, Early Hum Dev 85:705–712, 2009.
Allen DB, Cuttler L: Short stature in children–challenges and choices, N Engl J Med368(13):1220–1228, 2013.
Dezaki K: Ghrelin function in insulin release and glucose metabolism, Endocr Dev25:135–143, 2013.
Kageyama H, Takenoya F, Shiba K, etal: Neuronal circuits involving ghrelin in the hypothalamus-mediated regulation of feeding, Neuropeptides 44:133–138, 2010.
Lawson EA, Holsen LM, Santin M: Oxytocin secretion is associated with severity of disordered eating psychopathology and insular cortex hypoactivation in anorexia nervosa, J Clin Endocrinol Metab 97:E1898–E1908, 2012.
Lee HJ, Macbeth AH, Pagani JH, etal: Oxytocin: the great facilitator of life, Prog Neurobiol 88:127–151, 2009.
Lem AJ, de Rijke YB, van Toor H, etal: Serum thyroid hormone levels in healthy children from birth to adulthood and in short children born small for gestational age, J Clin Endocrinol Metab 97:3170–3178, 2012.
Thompson IR, Ciccone NA, Xu S, etal: GnRH pulse frequency-dependent stimulation of FSH ?transcription is mediated via activation of PKA and CREB, Mol Endocrinol27(4):606–618, 2013.
van Vught AJ, Nieuwenhuizen AG, Gerver WJ, etal: Pharmacological and physiological growth hormone stimulation tests to predict successful GH therapy in children, J Pediatr Endocrinol Metab 22:679–694, 2009.
Blanco EJ, Lane AH, Aijaz N, et al: Use of subcutaneous DDAVP in infants with central diabetes insipidus, J Pediatr Endocrinol Metab 19:919–925, 2006.
Djerman A, Elmaleh M, Simon D, et al: Central diabetes insipidus in infancy with or without hypothalamic adipsic hypernatremia syndrome: early identification and outcome, J Clin Endocrinol Metab 101:635–643, 2016.
Fenske W, Allolio B: Current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review, J Clin Endocrinol Metab 97:3426–3437, 2012.
Fenske W, Refardt J, Chifu I, et al: A copeptin-based approach in the diagnosis of diabetes insipidus, N Engl J Med 379(5):428–438, 2018.
Hoorn EJ, Zietse R: Water balance disorders after neurosurgery: the triphasic response revisited, NDT Plus 3:42–44, 2010.
Khan I, Zimmerman B, Brophy P, Kamath S: Masking of syndrome of inappropriate antidiuretic hormone secretion: the isonatremic syndrome, J Pediatr 165:722–726, 2014.
Knoers N, Monnens LH: Nephrogenic diabetes insipidus: clinical symptoms, pathogenesis, genetics and treatment, Pediatr Nephrol 6:476–482, 1992.
Majzoub JA, Muglia LJ, Srivatsa A: Disorders of the posterior pituitary. In Sperling MA, editor: Pediatric endocrinology, ed 4, Philadelphia, 2014, Elsevier.
Mandelblat-Cerf Y, et al: Bidirectional anticipation of future osmotic challenges by vasopressin neurons, Neuron 93(1):57–65, 2017.
Ranadive SA, Rosenthal SM: Pediatric disorders of water balance, Endocrinol Metab Clin North Am 38:663–672, 2009.
Richards GE, Thomsett MJ, Boston BA, et al: Natural history of idiopathic diabetes insipidus, J Pediatr 159:566–570, 2011.
Albanese A, Hindmarsh P, Stanhope R: Management of hyponatremia in patients with acute cerebral insults, Arch Dis Child 85:246–251, 2001.
Almond CS, Shin AY, Fortescue EB, et al: Hyponatremia among runners in the Boston Marathon, N Engl J Med 352:1550–1556, 2005.
Feldman BJ, Rosenthal SM, Vargas GA, et al: Nephrogenic syndrome of inappropriate antidiuresis, N Engl J Med 352:1884–1890, 2005.
Goldsmith SR: Treatment options for hyponatremia in heart failure, Heart Fail Rev 14:65–73, 2009.
Huang EA, Feldman BJ, Schwartz ID, et al: Oral urea for the treatment of chronic syndrome of inappropriate antidiuresis in children, J Pediatr 148:128–131, 2006.
Muglia LJ, Srivatsa A, Majzoub JA: Disorders of the posterior pituitary. In Sperling MA, editor: Pediatric endocrinology, ed 4, Philadelphia, 2014, WB Saunders.
Rivkees S: Differentiating appropriate antidiuretic hormone secretion, inappropriate antidiuretic hormone secretion and cerebral salt wasting: the common, uncommon, and misnamed, Curr Opin Pediatr 20(4):448–452, 2008.
Robertson GL: Vaptans for the treatment of hyponatremia, Nat Rev Endocrinol 7:151–161, 2011.
Root AW: Disorders of aldosterone synthesis, secretion, and cellular function, Curr Opin Pediatr 26:480–486, 2014.
Sterns RH, Silver SM: Cerebral salt wasting versus SIADH: what difference? J Am Soc Nephrol 19:194–196, 2008.
Agustsson TT, Baldvinsdottir T, Jonasson JG, et al: The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study, Eur J Endocrinol 173(5):655–664, 2015.
Lane C, Milne E, Freeth M: Cognition and behaviour in sotos syndrome: a systematic review, PLoS ONE 11(2):e0149189, 2016.
Lemire G, Gauthier J, Soucy JF, Delrue MA: A case of familial transmission of the newly described DNMT3A-ovwegrowth syndrome, Am J Med Genet 2017. doi:10.1002/ajmg.a.38119. [Epub ahead of print].
Liu Y, Yao Y, Xing B, et al: Prolactinomas in children under 14. Clinical presentation and long-term follow-up, Childs Nerv Syst 31(6):909–916, 2015.
Melmed S, Casanueva FF, Hoffman AR, et al: Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab 96(2):273, 2011.
Molitch ME: Diagnosis and treatment of pituitary adenomas—a review, JAMA 317(5):516–524, 2017.
Rostomyan L, Daly AF, Beckers A: Pituitary gigantism: causes and clinical characteristics, Ann Endocrinol (Paris) 76(6):643–649, 2015.
Tatton-Brown K, Loveday C, Yost S, et al: Mutations in epigenetic regulation genes are a major cause of overgrowth with intellectual disability, Am J Hum Genetics 100:725–736, 2017.
Tatton-Brown K, Seal S, Ruark E, et al: Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability, Naure genetics 46(4):385–388, 2014.
Trivellin G, Daly AF, Faucz B, et al: Gigantism and acromegaly due to xq26 microduplications and GPR101 mutation, N Engl J Med 371(25):2363–2374, 2014.
Vroonen L, Lancellotti P, Garcia MT, et al: Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia, Endocrine 55(1):239–245, 2017.
Wells SA Jr: Progress in endocrine neoplasia, Clin Cancer Res 22(20):4981–4988, 2016
Abreu AP, Macedo DA, Brito VN, et al: A new pathway in the control of the initiation of puberty: the MKRN3 gene, J Mol Endocrinol 54:R131–R139, 2015.
Aksglaede L, S?rensen K, Petersen JH, et al: Recent decline in age at breast development: the Copenhagen Puberty Study, Pediatrics 123:E932–E939, 2009.
Biro FM, Maida P, Galvez MP, et al: Pubertal assessment method and baseline characteristics in a mixed longitudinal study of girls, Pediatrics 126:E583–E590, 2010.
Lehman MN, Coolen LM, Goodman RL: Minireview: Kisspeptin/Neurokinin B/Dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormon secretion, Endocrinology 15:3479–3489, 2010.
Livadas S, Chrousos GP: Control of the onset of puberty, Curr Opin Pediatr 28:551–558, 2016.
Macedo DB, Silveira LF, Bessa DS, et al: Sexual precocity–genetic bases of central precocious puberty and autonomous gonadal activation, Endocr Dev 29:50–71, 2016.
Mouritsen A, Aksglaede L, Sorensen K, et al: The pubertal transition in 179 healthy Danish children: associations between pubarche, adrenarche, gonadarche and body composition, Eur J Endocrinol 168:129–136, 2012.
Plant TM: Neuroendocrine control of the onset of puberty, Front Neuroendocrinol 38:73–88, 2015.
Roa J, Garc?a-Galiano D, Castellano JM, et al: Metabolic control of puberty onset: new players, new mechanisms, Mol Cell Endocrinol 324:87–94, 2010.
Shaw ND, Butler PJ, McKinney SM, et al: Insights into puberty: the relationship between sleep stages and pulsatile LH secretion, J Clin Endocrinol Metab 97:E2055–E2062, 2012.
Shin YL: An update on the genetic causes of central precocious puberty, Ann Pediatr Endocrinol Metab 21:66–69, 2016.
Tomova A, Deepinder F, Robeva R, et al: Growth and development of male external genitalia, Arch Pediatr Adolesc Med 164:1152–1157, 2010.
Chalumeau M, Chemaitilly W, Trivin C, et al: Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities, Pediatrics 109:61–67, 2002.
Chemaitilly W, Merchant TE, Li Z, et al: Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tumours: presentation and long-term outcomes, Clin Endocrinol (Oxf) 84:361–371, 2016.
Dimitrova-Mladenova MS, Stefanova EM, Gluchkova M, et al: Males with paternally inherited MKRN3 mutations may be asymptomatic, J Pediatr 179:263–265, 2016.
Kaplowitz P, Bloch C: Evaluation and referral of children with signs of early puberty, Pediatrics 137(1):e20153732, 2016.
Kaplowitz PB: Do 6-8-year-old girls with central precocious puberty need routine brain imaging?, Int J Pediatr Endocrinol 9:2016, 2016.
Latronico AC, Brito VN, Carel JC: Causes, diagnosis, and treatment of central precocious puberty, Lancet Diabetes Endocrinol 4:265–274, 2016.
Lee PA, Klein K, Mauras N, et al: Efficacy and safety of leuprolide acetate 3 month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty, J Clin Endocrinol Metab 97:1572–1580, 2012.
Mogensen SS, Aksglaede L, Mouritsen A, et al: Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty, J Clin Endocrinol Metab 96:1393–1401, 2011.
Sathasivam A, Garibaldi L, Shapiro S, et al: Leuprolide stimulation testing for the evaluation of early female sexual maturation, Clin Endocrinol (Oxf) 73:375–381, 2010.
Silverman LA, Neely EK, Kletter GB, et al: Long-Term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial, J Clin Endocrinol Metab 100:2354–2363, 2015.
The Medical Letter: Triptorelin (triptodur) for central precocious puberty, Med Lett Drugs Ther 60(1537):7–8, 2018.
Bizzarri C, Bottaro G: Endocrine implications of neurofibromatosis 1 in childhood, Horm Res Paediatr 83:232–241, 2015.
Boot AM, Lumbroso S, Verhoef-Post M, et al: Mutation analysis of the LH receptor gene in Leydig cell adenoma and hyperplasia and functional and biochemical studies of activating mutations of the LH receptor gene, J Clin Endocrinol Metab 96:E1197–E1205, 2011.
Gan HW, Phipps K, Aquilina K, et al: Neuroendocrine morbidity after pediatric optic gliomas: a longitudinal analysis of 166 children over 30 years, J Clin Endocrinol Metab 100:3787–3799, 2015.
Carel J, Eugster E, Rogol A, et al: Consensus statement on the use of gonadotropin-releasing hormone analogs in children, Pediatrics 123:E752–E762, 2009.
Eugster EA: The use of gonadotropin-releasing hormone analogs beyond precocious puberty, J Pediatr 167(2):481–485, 2015.
Thornton P, Silverman LA, Geffner ME, et al: Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty, Pediatr Endocrinol Rev 11:306–317, 2014.
Stephen MD, Zage PE, Waguespack SG: Gonadotropin-dependent precocious puberty: neoplastic causes and endocrine considerations, Int J Pediatr Endocrinol 2011:184502, 2011.
Estrada A, Boyce AM, Brillante BA, et al: Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome, Eur J Endocrinol 175:477–483, 2016.
Wit JM, Hero M, Nunez SB: Aromatase inhibitors in pediatrics, Nat Rev Endocrinol 8:135–147, 2011.
Atay Z, Yesilkaya E, Erdeve SS, et al: The etiology and clinical features of non-CAH gonadotropin-independent precocious puberty: a multicenter study, J Clin Endocrinol Metab 101:1980–1988, 2016.
Marakaki C, Karapanou O, Gryparis A, et al: Early adiposity rebound and premature adrenarche, J Pediatr 186:72–77, 2017.
Achermann JC, Jameson JL: Advances in the molecular genetics of hypogonadotropic hypogonadism, J Pediatr Endocrinol Metab 14:3, 2001.
Argente J: Diagnosis of late puberty, Horm Res 51(Suppl 3):95, 1999.
Brook CGD: Treatment of late puberty, Horm Res 51(Suppl 3):101, 1999.
Hagen CP, Aksglaede L, Sorensen K, et al: Serum levels of anti-mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 turner syndrome patients, J Clin Endocrinol Metab 95:11, 2010.
Topaloglu AK, Reimann F, Guclu M, et al: TAC3 and TACR3 mutations in familial hypogonadotrophic hypogonadism reveal a key role for neurokinin B in the central control of reproduction, Nat Genet 41:3, 2009.
Bianco AC, Salvatore D, Gereben B, et al: Biochemistry, cellular, and molecular biology, and physiological roles of the iodothyronine selenodeiodinases, Endocr Rev 23(1):38–89, 2002.
Caldwell KL, Pan Y, Mortensen ME, et al: Iodine status in pregnant women in the National Children’s Study and in U.S. women (15-44 years), National Health and Nutrition Examination Survey 2005-2010, Thyroid 23(8):927–937, 2013.
Carrasco N: Thyroid synthesis and secretion. In Braverman LE, Cooper DS, editors: Werner & Ingbar’s the thyroid: a fundamental and clinical text, ed 10, Philadelphia, 2013, Lippincott Williams & Wilkins, pp 32–47.
De Felice M, Di Lauro F: Thyroid development and its disorders: genetics and molecular mechanisms, Endocr Rev 25(5):722–746, 2004.
Kopp P: Thyroid hormone synthesis. In Braverman LE, Cooper DS, editors: Werner & Ingbar’s the thyroid: a fundamental and clinical text, ed 10, Philadelphia, 2013, Lippincott Williams & Wilkins, pp 48–73.
Pearce EN: Iodine nutrition in the UK: what went wrong?, Lancet 377(9782):1979–1980, 2011.
Santisteban P: Development and anatomy of the hypothalamic-pituitary-thyroid axis. In Braverman LE, Cooper DS, editors: Werner & Ingbar’s the thyroid: a fundamental and clinical text, ed 10, Philadelphia, 2013, Lippincott Williams & Wilkins, pp 4–23
Baloch Z, Carayon P, Conte-Devolx B, et al: Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease, Thyroid 13(1):3–126, 2003.
Fisher DA, Brown RS: The maturation of thyroid function in the perinatal period and during childhood. In Braverman LE, Cooper DS, editors: Werner & Ingbar’s the thyroid: a fundamental and clinical text, ed 10, Philadelphia, 2013, Lippincott Williams & Wilkins, pp 775–786.
Kaloumenou I, Alevizaki M, Ladopoulos C, et al: Thyroid volume and echostructure in schoolchildren living in an iodine-replete area: relation to age, pubertal stage, and body mass index, Thyroid 17(9):875–881, 2007.
Lem AJ, de Rijke YB, van Toor H, et al: Serum thyroid hormone levels in healthy children from birth to adulthood and in short children born small for gestational age, J Clin Endocrinol Metab 97(9):3170–3178, 2012.
Thalmann S, Meier CA: Effects of drugs on TSH secretion, thyroid hormones absorption, synthesis, metabolism, and action. In Braverman LE, Cooper DS, editors: Werner & Ingbar’s the thyroid: a fundamental and clinical text, ed 10, Philadelphia, 2013, Lippincott Williams & Wilkins, pp 187-202.
Williams FL, Mires GJ, Barnett C, et al: Transient hypothyroxinemia in preterm infants: the role of cord sera thyroid hormone levels adjusted for prenatal and intrapartum factors, J Clin Endocrinol Metab 90(8):4599–4606, 2005.
Benvenga S: Thyroid hormone transport proteins and the physiology of hormone binding. In Braverman LE, Cooper DS, editors: Werner & Ingbar’s the thyroid: a fundamental and clinical text, ed 10, Philadelphia, 2013, Lippincott Williams & Wilkins, pp. 93–102.
LaFranchi SH, Snyder DB, Sesser DE, et al: Follow-up of newborns with elevated screening T4 concentrations, J Pediatr 143(3):296–301, 2003.
Pappa T, Ferrara AM, Refetoff S: Inherited defects of thyroxine-binding proteins, Best Pract Res Clin Endocrinol Metab 29(5):735–747, 2015.
American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, et al: Update of newborn screening and therapy for congenital hypothyroidism, Pediatrics 117:2290–2303, 2006.
Azzolini S, Nosadini M, Balzarin M, et al: Delayed myelination is not a constant feature of Allan-Herndon-Dudley syndrome: report of a new case and review of the literature, Brain Dev 36:716–720, 2014.
Balhara B, Misra M, Levitsky LL: Clinical monitoring guidelines for congenital hypothyroidism: laboratory outcome data in the first year of life, J Pediatr 158:532–537, 2011.
Bochukova E, Schoenmakers N, Agostine M, et al: A mutation in the thyroid hormone receptor alpha gene, N Engl J Med 366:243–249, 2012.
Bongers-Schokking JJ, de Muinck Keizer-Schrama SM: Influence of timing and dose of thyroid hormone replacement on mental, psychomotor, and behavioral development in children with congenital hypothyroidism, J Pediatr 147:768–774, 2005.
Bongers-Schokking JJ, Resing WC, de Rijke YB, et al: Cognitive development in congenital hypothyroidism: is overtreatment a greater threat than undertreatment? J Clin Endocrinol Metab 98:4499–4506, 2013.
Bonomi M, Busnelli M, Beck-Peccoz P, et al: A family with complete resistance to thyrotropin-releasing hormone, N Engl J Med 360:731–734, 2009.
Carre A, Szinnai G, Castanet M, et al: Five new TTF1/NKX2.1 mutations in brain-lung-thyroid syndrome: rescue by PAX8 synergism in one case, Hum Mol Genet 18:2266–2276, 2009.
Carswell JM, Gordon JH, Popovsky E, et al: Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism, J Clin Endocrinol Metab 98:610–617, 2012.
Connelly K, Boston B, Pearce E, et al: Congenital hypothyroidism caused by excess prenatal maternal iodine ingestion, J Pediatr 161:760–762, 2012.
De Marco G, Agretti P, Montanelli L, et al: Identification and functional analysis of novel dual oxidase 2 (DUOX2) mutations in children with congenital or subclinical hypothyroidism, J Clin Endocrinol Metab 96:E1335, 2011.
Gelb A, Demeterco-Berggren C, Jones KL: Unawareness of the effects of soy intake on the management of congenital hypothyroidism, Pediatrics 130: e699–e702, 2012.
Groters A, Krude H: Detection and treatment of congenital hypothyroidism, Nat Rev Endocrinol 18:104–113, 2011.
Hao X, Liu S, Wu X, et al: Infantile mitochondrial disorder associated with subclinical hypothyroidism is caused by a rare mitochondrial DNA 8691A> G mutations: a case report, Cell Molec Dev Neurosci 26(10):588–592, 2015.
Harris KB, Pass KA: Increase in congenital hypothyroidism in New York State and in the United States, Mol Genet Metab 91:268, 2007.
Jin HY, Heo SH, Kim YM, et al: High frequency of DUOX2 mutations in transient or permanent congenital hypothyroidism with eutopic thyroid glands, Horm Res Paediatr 82:252–260, 2014.
Kim SY, Lee YA, Jung HW, et al: Pediatric goiter: can thyroid disorders bepredicted at diagnosis and in follow-up?, J Pediatr 170:253–259, 2016.
Kopp P, Bizhanova A: Clinical and molecular characteristics of Pendred syndrome, Ann Endocrinol (Paris) 72:88–94, 2011.
LaFranchi SH: Newborn screening strategies for congenital hypothyroidism: an update, J Inherit Metab Dis 33(Suppl 2):S225–S233, 2010.
LaFranchi SH: Approach to the diagnosis and treatment of neonatal hypothyroidism, J Clin Endocrinol Metab 96:2959–2967, 2011.
Lazarus JH, Bestwick JP, Channon S, et al: Antenatal thyroid screening and childhood cognitive function, N Engl J Med 366:493–500, 2012.
Leger J: Congenital hypothyroidism: a clinical update of long-term outcome in young adults, Eur J Endocrinol 172:R67–R77, 2015.
Loger J, Ecosse E, Roussey M, et al: Subtle health impairment and socioeducational attainment in young adult patients with congenital hypothyroidism diagnosed by neonatal screening: a longitudinal population-based cohort study, J Clin Endocrinol Metab 96:2011, 1771.
Loger J, Olivieri A, Donaldson M, et al: European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism, J Clin Endocrinol Metab 99:363, 2014.
Li L, Deheragoda M, Lu Y, et al: Hypothyroidisn associated with ATP8B1 deficiency, J Pediatr 167:1334–1339, 2015.
Lilley JS, Lomenick JP: Delayed diagnosis of hypothyroidism following excision of a thyroglossal duct cyst, J Pediatr 162:427–428, 2013.
Mathai S, Cutfield WS, Gunn AJ, et al: A novel therapeutic paradigm to treat congenital hypothyroidism, Clin Endocrinol (Oxf) 69:142–147, 2008.
Narumi S, Muroya K, Asakura Y, et al: Transcription factor mutations and congenital hypothyroidism: systematic genetic screening of a population-based cohort of Japanese patients, J Clin Endocrinol Metab 95:2010, 1981.
Nebesio TD, McKenna MP, Nabhan ZM, et al: Newborn screening results in children with central hypothyroidism, J Pediatr 156:990, 2010.
Nicholas AK, Serra EG, Cangul H, et al: Comprehensive screening of eight known causative genes in congenital hypothyroidism with gland-in-situ, J Clin Endocrinol Metab 101:4521–4531, 2016.
Oliveri A, Corbetta C, Weber G, et al: Congenital hypothyroidism due to defects of thyroid development and mild increase of TSH at screening: data from the Italian Registry of Infants with Congenital Hypothyroidism, J Clin Endocrinol Metab 98:1403–1408, 2013.
Olney RS, Grosse SD, Vogt RF Jr: Prevalence of congenital hypothyroidism — current trends and future directions: workshop summary, Pediatrics 125:S31–S36, 2010.
Partsch CJ, Riepe FG, Krone N, et al: Initially elevated TSH and congenital hypothyroidism due to a homozygous mutation of the TSH beta subunit gene: case report and review of the literature, Exp Clin Endocrinol Diabetes 114:227–234, 2006.
Persani L, Gelmini G, Marelli F, et al: Syndromes of resistance to TSH, Ann Endocrinol (Paris) 72:60, 2011.
Perry R, Heinrichs C, Bourdoux P, et al: Discordance of monozygotic twins for thyroid dysgenesis: implications for screening and for molecular pathophysiology, J Clin Endocrinol Metab 87(9):4072–4077, 2002.
Peteiro-Gonzalez D, Lee J, Rodriguez-Fontan J, et al: New insights into thyroglobulin pathophysiology revealed by the study of a family with congenital goiter, J Clin Endocrinol Metab 95:3522, 2010.
Rabbiosi S, Vigone MC, Cortinovis F, et al: Congenital hypothyroidism with eutopic gland: analysis of clinical and biochemical features at diagnosis and after re-evaluation, J Clin Endocrinol Metab 98:1395–1402, 2013.
Ramos HE, Labedan I, Carre A, et al: New cases of isolated congenital central hypothyroidism due to homozygous thyrotropin beta mutations: a pitfall to neonatal screening, Thyroid 20:639–645, 2010.
Ris-Stalpers C, Bikker H: Genetics and phenomics of hypothyroidism and goiter due to TPO mutations, Mol Cell Endocrinol 322:38, 2010.
Rivkees SA, Bode HH, Crawford JD: Long-term growth in juvenile acquired hypothyroidism: the failure to achieve normal adult stature, N Engl J Med 318:599–602, 1988.
Schwartz CE: The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome, Best Pract Res Clin Endocrinol Metab 21:307–321, 2007.
Selva KA, Harper A, Downs A, et al: Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH, J Pediatr 147:775–780, 2005.
Spitzweg C, Morris JC: Genetics and phenomics of hypothyroidism and goiter due to NIS mutations, Mol Cell Endocrinol 322:56, 2010.
Stoppa-Vaucher S, Van Vliet G, Delado?y J: Variation by ethnicity in the prevalence of congenital hypothyroidism due to thyroid dysgenesis, Thyroid 21:13, 2011.
Supakul N, Delaney LR, Siddiqui AR, et al: Ultrasound for primary imaging of congenital hypothyroidism, AJR Am J Roentgenol 199:W360–W366, 2012.
Syed S: Iodine and the “near” eradication of cretinism, Pediatrics 135(4):594–596, 2015.
Van Dop C, Conte FA, Koch TK, et al: Pseudotumor cerebri associated with initiation of levothyroxine therapy for juvenile hypothyroidism, N Engl J Med 308:1076–1080, 1983.
Van Tijn DA, de Vijlder JJ, Verbeeten B Jr, et al: Neonatal detection of congenital hypothyroidism of central origin, J Clin Endocrinol Metab 90:3350–3359, 2005.
Van Wyk JJ, Grumbach MM: Syndrome of precocious menstruation and galactorrhea in juvenile hypothyroidism: an example of hormonal overlap in pituitary feedback, J Pediatr 57:416–435, 1960.
Woo HC, Lizarda A, Tucker R, et al: Congenital hypothyroidism with a delayed thyroid-stimulating hormone elevation in very premature infants: incidence and growth and developmental outcomes, J Pediatr 158:538–542, 2011.
Zeitler P, Solberg P, Pharmacy and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society: Food and levothyroxine administration in infants and children, J Pediatr 157:13, 2010.
Bhandare N, Kennedy L, Malyapa RS, et al: Primary and central hypothyroidism after radiotherapy for head-and-neck tumors, Int J Radiat Oncol Biol Phys 68:1131–1139, 2007.
Bilimoria KY, Pescovitz OH, DiMeglio LA: Autoimmune thyroid dysfunction in children with type 1 diabetes mellitus: screening guidelines based on a retrospective analysis, J Pediatr Endocrinol Metab 16:1111–1117, 2003.
Bjorn AM, Bojesen A, Gravholt CH, et al: Hypothyroidism secondary to hypothalamic-pituitary dysfunction may be part of the phenotype in Klinefelter syndrome: a case-control study, J Clin Endocrinol Metab 94:2478, 2009.
Cooper DS, Biondi B: Subclinical thyroid disease, Lancet 379:1142–1152, 2012.
de Vries L, Bulvick S, Phillip M: Chronic autoimmune thyroiditis in children and adolescents: at presentation and during long-term follow-up, Arch Dis Child 94:33–37, 2009
El-Mansoury M, Bryman I, Berntorp K, et al: Hypothyroidism is common in Turner syndrome: results of a five-year follow-up, J Clin Endocrinol Metab 90:2131–2135, 2005.
Feingold SB, Smith J, Houtz J, et al: Prevalence and functional significance of thyrotropin receptor blocking antibodies in children and adolescents with chronic lymphocytic thyroiditis, J Clin Endocrinol Metab 94:4742, 2009.
Kim SH, Chung HR, Kim Sh, et al: Valproic acid therapy causes subclinical hypothyroidism in children with epilepsy, Neuropediatrie 43:135–139, 2012.
Lazar L, Frumkin RB, Battat E, et al: Natural history of thyroid function tests over 5 years in a large pediatric cohort, J Clin Endocrinol Metab 94:1678–1682, 2009.
Lazarus J, Brown RS, Daumerie C, et al: 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children, Eur Thyroid J 3:76–94, 2014.
The Medical Letter: drugs for hypothyroidism, Med Lett 57(1480):147–150, 2015.
Nambam B, Winter WE, Schatz DA: IgG4 antibodies in autoimmune polyglandular disease and IgG4-related endocrinopathies: pathophysiology and clinical characteristics, Curr Opin Pediatr 26:493–499, 2014.
Pollock AJ, Seibert T, Allen DB: Severe and persistent thyroid dysfunction associated with tetracycline-antibiotic treatment in youth, J Pediatr 173:232–234, 2016.
Popova G, Paterson WF, Brown A, et al: Hashimoto’s thyroiditis in Down’s syndrome: clinical presentation and evolution, Horm Res 70:278–284, 2008.
Sattar N, Lazare F, Kacer M, et al: Celiac disease in children, adolescents, and young adults with autoimmune thyroid disease, J Pediatr 158:272–275, 2011.
Schneller C, Finkel L, Wise M, et al: Autoimmune polyendocrine syndrome: a case-based review, Pediatr Ann 42:203–207, 2013.
Sindoni A, Rodolico C, Pappalardo MA, et al: Hypothyroid myopathy: a peculiar clinical presentation of thyroid failure. Review of the literature, Rev Endocr Metab Disord 17(4):499–519, 2016.
Vlachopapadopoulou E, Thomas D, Karachaliou F, et al: Evolution of sonographic appearance of the thyroid gland in children with Hashimoto’s thyroiditis, J Pediatr Endocrinol Metab 22:339–344, 2009.
Brown RS: Autoimmune thyroiditis in childhood, J Clin Res Pediatr Endocrinol 5(Suppl 1):45–49, 2013.
de Vries L, Bulvik S, Phillip M: Chronic autoimmune thyroiditis in children and adolescents: at presentation and during long-term follow-up, Arch Dis Child94:33–37, 2009.
Fava A, Oliverio R, Giuliano S, etal: Clinical evolution of autoimmune thyroiditis in children and adolescents, Thyroid 19:361–367, 2009.
Feinbold SB, Smith J, Houtz J, etal: Prevalence and functional significance of thyrotropin receptor blocking antibodies in children and adolescents with chronic lymphocytic thyroiditis, J Clin Endocrinol Metab 94:4742–4748, 2009.
Lazarus J, Brown RS, Daumerie C, etal: 2014 European Thyroid Association guidelines for the management of subclinical hypothyroidism in pregnancy and in children, Eur Thyroid J 3:76–94, 2014.
Paes JE, Burman KD, Cohen J, etal: Acute bacterial suppurative thyroiditis: a clinical review and expert opinion, Thyroid 20:247, 2010.
Scarpa V, Kousta E, Tertipi A, etal: Treatment with thyroxine reduces thyroid volume in euthyroid children and adolescents with chronic autoimmune thyroiditis, Horm Res Paediatr 73:61–67, 2010.
Yoshida A, Hisatome I, Taniguchi S, etal: Pendrin is a novel autoantigen recognized by patients with autoimmune thyroid diseases, J Clin Endocrinol Metab 94(2):442–448, 2009.
Vlachopapadopoulou E, Thomas D, Karachaliou F, etal: Evolution of sonographic appearance of the thyroid gland in children with Hashimoto’s thyroiditis, J Pediatr Endocrinol Metab 22:339–344, 2009.
Bizhanova A, Kopp P: Minireview: the sodium-iodide symporter NIS and pendrin in iodide homeostasis of the thyroid, Endocrinology 150(3):1084–1090, 2009.
Bottcher Y, Eszlinger M, Tonjes A, Paschke R: The genetics of euthyroid familial goiter, Trends Endocrinol Metab 16(7):314–319, 2005.
Hashimoto H, Hashimoto K, Suehara N: Successful in utero treatment of fetal goitrous hypothyroidism: case report and review of the literature, Fetal Diagn Ther 21(4):360–365, 2006.
Koksal N, Akt?rk B, Saglan H, et al: Reference values for neonatal thyroid volumes in a moderately iodine-deficient area, J Endocrinol Invest 31(7):642–646, 2008.
Benmiloud M, Chaouki ML, Gutekunst R, et al: Oral iodized oil for correcting iodine deficiency: optimal dosing and outcome indicator selection, J Clin Endocrinol Metab 79(1):20–24, 1994.
Boyages SC, Halpern JP, Maberly GF, et al: A comparative study of neurological and myxedematous endemic cretinism in western China, J Clin Endocrinol Metab 67(6):1262–1271, 1988.
DeLange F: Iodine deficiency as a cause of brain damage, Postgrad Med J 77(906):217–220, 2001.
Fuse Y, Saito N, Tsuchiya T, et al: Smaller thyroid gland volume with high urinary iodine excretion in Japanese schoolchildren: normative reference values in an iodine-sufficient area and comparison with the WHO/ICCIDD reference, Thyroid 17(2):145–155, 2007.
Pearce EN, Andersson M, Zimmermann MB: Global iodine nutrition: where do we stand in 2013?, Thyroid 23(5):523–528, 2013.
World Health Organization, United Nations Children’s Fund, and International Council for the Control of Iodine Deficiency Disorders: Assessment of the iodine deficiency disorders and monitoring their elimination, 3rd ed, Geneva, 2007, World Health Organization.
Akcurin S, Turkkahraman D, Tysoe C, et al: A family with a novel TSH receptor activating germline mutation (p. Ala485val), Eur J Pediatr 167:1231–1237, 2008.
Brix TH, Kyvik KO, Hegedus L: Major role of genes in the etiology of simple goiter in females: a population-based twin study, J Clin Endocrinol Metab 84:3071–3075, 1999.
De Vries L, Bulvik S, Phillip M: Chronic autoimmune thyroiditis in children and adolescents: at presentation and during long-term follow-up, Arch Dis Child 94:33–37, 2009.
Gopalakrishnan S, Chugh PK, Chhillar M, et al: Goitrous autoimmune thyroiditis in a pediatric population: a longitudinal study, Pediatrics 122:e670–e674, 2008.
Abbasi B, Sharif Z: Sprabery LR: hypokalemic thyrotoxic periodic paralysis with thyrotoxic psychosis and hypercapnic respiratory failure, Am J Med Sci 340(2):147–153, 2010.
Andersen SL, Olsen J, Wu CS, Laurberg P: Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study, J Clin Endocrinol Metab 98(11):4373–4381, 2013.
Bahn RS: Graves ophthalmopathy, N Engl J Med 362(8):726–736, 2010.
Bahn RS, Burch HB, Cooper DS, et al: Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American thyroid Association and American Association of Clinical Endocrinologists, Thyroid 21(6):593–646, 2011.
Barrio R, Lopez-Capape M, Martinez-Badas I, et al: Graves disease in children and adolescents: response to long-term treatment, Acta Paediatr 94(11):2005, 1583.
Bauer AJ: Approach to the pediatric patient with Graves disease: when is definitive therapy warranted?, J Clin Endocrinol Metab 96(3):580–588, 2011.
Brent GA: Graves disease, N Engl J Med 358:2594–2605, 2008.
Cassio A, Corrias A, Gualandi S, et al: Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis: results of a collaborative study, Clin Endocrinol (Oxf) 64(1):53–57, 2006.
Chu X, Pan CM, Zhao SX, et al: A genome-wide association study identifies two new risk loci for Graves disease, Nat Genet 43(9):897–901, 2011.
De Leo S, Lee SY, Braverman LE: Hyperthryroidism, Lancet 388:906–916, 2016.
Food and Drug Administration: FDA Drug Safety Communication: New boxed warning on severe liver injury with propylthiouracil. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm209023.htm.
Gastaldi R, Poggi E, Mussa A, et al: Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers, J Pediatr 164(5):1189–1194, 2014.
Glaser NS, Styne DM: Predicting the likelihood of remission in children with Graves disease: a prospective, multicenter study, Pediatrics 12(3):e481–e488, 2008.
Goldstein SM, Katoqitz WR, Moshang T, et al: Pediatric thyroid-associated orbitopathy: the Children’s Hospital of Philadelphia experience and literature review, Thyroid 18(9):997–999, 2008.
Kaguelidou F, Alberti C, Castanet M, et al: Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment, J Clin Endocrinol Metab 93(10):3817, 2008.
Lee HJ, Li CW, Hammerstad SS, et al: Immunogenetics of autoimmune thyroid diseases: a comprehensive review, J Autoimmun 64:82–90, 2015.
Leger J, Gelwane G, Kaguelidou F, et al: Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves disease: national long-term cohort study, J Clin Endocrinol Metab 97(1):110–119, 2012.
Lytton SD, Li Y, Olivo PD, et al: Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins, Clin Exp Immunol 162(3):436–438, 2010.
Laurberg P, Wallin G, Tallstedt L, et al: TSH-receptor autoimmunity in Graves disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study, Eur J Endocrinol 158(1):69–75, 2008.
Pinto T, Cummings EA, Barnes D, et al: Clinical course of pediatric and adolescent Graves disease treated with radioactive iodine, J Pediatr Endocrinol Metab 20(9): 973–980, 2007.
Okawa ER, Grant FD, Smith JR: Pediatric Graves disease: decisions regarding therapy, Curr Opin Pediatr 27(4):442–447, 2015.
Regina A, Majlesi N: Thyrotoxicosis after consumption of dietary supplements purchased through the internet—Staten Island, New York, 2015, MMWR Morb Mortal Wkly Rep 65(13):353–354, 2016.
Rivkees SA, Mattison DR: Ending propylthiouracil-induced liver failure in children, N Engl J Med 360(15):1574–1575, 2009.
Rivkees SA: Pediatric Graves disease: controversies in management, Horm Res Paediatr 74(5):305–331, 2010.
Ross DS, Burch HB, Cooper DS, et al: American Thyroid Association guidelines for the diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis, Thyroid 26(10):1343–1421, 2016.
Smith TJ, Hegedus L: Graves disease, N Engl J Med 375(16):1552–1565, 2016.
Smith TJ, Kahaly GJ, Ezra DG: Teprotumumab for thyroid-associated ophthalmopathy, N Engl J Med 376:1748–1761, 2017.
Alexander AK, Pearce EN, Brent GA, et al: 2017 guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum, Thyroid 27(3):315–389, 2017.
Chan W, Wong GW, Fan DS, et al: Ophthalmopathy in childhood Graves disease, Br J Ophthalmol 86(7):740, 2002.
Chester J, Rotenstein D, Ringkananont U, et al: Congenital neonatal hyperthyroidism caused by germline mutations in the TSH receptor gene, J Pediatr Endocrinol Metab 21(5):479–486, 2008.
Kempers MJ, van Tijn DA, van Trotsenburg AS, et al: Central congenital hypothyroidism due to gestational hyperthyroidism: detection where prevention failed, J Clin Endocrinol Metab 88(12):5851–5857, 2003.
Leger J: Management of fetal and neonatal Graves disease, Horm Res Paediatr 87(1):1–6, 2017.
Lewis KA, Engle W, Hainline BE, et al: Neonatal Graves disease associated with severe metabolic abnormalities, Pediatrics 128(1):e232–e236, 2011.
Mastorakos G, Mitsiades NS, Doufas AG, et al: Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report, Thyroid 7(7):433–439, 1997.
van der Kaay DCM, Wasserman J, Palmert M: Management of neonates born to mothers with Graves disease, Pediatrics 137(4):2016.
Brito JP, Morris JC, Montori VM: Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours, BMJ 347:18–21, 2013.
Brose MS, Nutting CM, Jarzab B, et al: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial, Lancet 384:319–328, 2014.
Cappola AR: How to look for thyroid cancer, JAMA 317(18):1840–1841, 2017.
Davies SM: Subsequent malignant neoplasms in survivors of childhood cancer: Childhood Cancer Survivor Study (CCSS) studies, Pediatr Blood Cancer 48:727–730, 2007.
Francis GL, Waguespack SG, Bauer AJ, et al: Management guidelines for children with thyroid nodules and differentiated thyroid cancer, American Thyroid Associations guidelines, Thyroid 25(7):716–759, 2015.
Handkiewicz-Junak D, Wloch J, Roskosz J, et al: Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer, J Nucl Med 48:879–888, 2007.
Lazar L, Lebenthal Y, Steinmetz A, et al: Differentiated thyroid cancer in pediatric patients: comparison of presentation and course between prepubertal children and adolescents, J Pediatr 154:708–714, 2009.
Lim H, Devesa SS, Sosa JA, et al: Trends in thyroid cancer incidence and mortality in the United States, 1974-2013, JAMA 317(13):1338–1348, 2017.
Machens A, Lorenz K, Thanh PN, et al: Papillary thyroid cancer in children and adolescents does not differ in growth patterns and metastatic behavior, J Pediatr 157:648–652, 2010.
Mendelsohn AH, Elashoff DA, Abemayor E, et al: Surgery for papillary thyroid carcinoma, Arch Otolaryngol Head Neck Surg 136(11):1055–1061, 2010.
Nikiforov YE, Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer, Nat Rev Endocrinol 7:569–580, 2011.
Palmer BA, Zarroug AE, Poley RN, et al: Papillary thyroid carcinoma in children: risk factors and complications of disease recurrence, J Pediatr Surg 40:1284–1288, 2005.
Rutter MM, Jha P, Schultz KA, et al: DICER 1 mutations and differentiated thyroid carcinoma: evidence of a Direct Association, J Clin Endocrinol Metab 101(1):1–5, 2016.
Schlumberger M, Catargi B, Borget I, et al: Strategies of radioiodine ablation in patients with low-risk thyroid cancer, N Engl J Med 366:1663–1672, 2012.
Scholz S, Smith JR: An experienced pediatric thyroid surgery team can perform thyroid surgery with a low rate of complications similar to that of high-volume adult thyroid surgeons, J Pediatr Surg 46:437–442, 2011.
Seaberg RM, Eski S, Freeman JL: Influence of previous radiation exposure on pathologic features and clinical outcome in patients with thyroid cancer, Arch Otolaryngol Head Neck Surg 135:355–359, 2009.
Smith JR, et al: Children with mutations in the PTEN gene can develop thyroid nodules and thyroid cancer at a younger age than previously appreciated, J Clin Endocrinol Metab 96:34–37, 2011.
Vaccarella S, Franceschi S, Bray F, et al: Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis, N Engl J Med 375(7):614–617, 2016.
Veiga LHS, Lubin JH, Anderson H, et al: A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer, Radiat Res 178(4):365–376, 2012.
Vergamini LB, Frazier AL, Abrantes FL, et al: Increase in the incidence of differentiated thyroid carcinoma in children, adolescents, and young adults: a population-based study, J Pediatr 164:1481–1485, 2014.
Wells SA, Asa SL, Dralle H, et al: Revised American Thyroid Association guidelines for the management of medullary thyroid cancer, Thyroid 25:567–610, 2015.
Xing M, Haugen BR, Schlumberger M: Progress in molecular-based management of differentiated thyroid cancer, Lancet 381:1058–1066, 2013.
Xing M: Molecular pathogenesis and mechanisms of thyroid cancer, Nat Rev Cancer 13:184–199, 2013.
Bauer AJ, Francis GL: Evaluation and management of thyroid nodules in children, Curr Opin Pediatr 28:536–544, 2016.
Burman KD, Wartofsky L: Thyroid nodules, N Engl J Med 373(24):2347–2356, 2015.
Cibas ES, Ali SZ: The Bethesda system for reporting thyroid cytopathology, Thyroid 19(11):1159–1165, 2009.
Durante C, Costante G, Lucisano G, et al: The natural history of benign thyroid nodules, JAMA 313(9):926–935, 2015.
Francis GL, Waguespack SG, Bauer AJ, et al: Management guidelines for children with thyroid nodules and differentiated thyroid cancer, American Thyroid Associations guidelines, Thyroid 25(7):716–759, 2015.
Gupta A, Ly S, Castroneves LA, et al: A standardized assessment of thyroid nodules in children confirms higher cancer prevalence than in adults, J Clin Endocrinol Metab 98(8):3238–3245, 2013.
Gupta A, Ly S, Castroneves LA, et al: How are childhood thyroid nodules discovered: opportunities for improving early detection, J Pediatr 164:658–660, 2014.
Jameson JL: Minimizing unnecessary surgery for thyroid nodules, N Engl J Med 367:765–767, 2012.
Josefson J, Zimmerman D: Thyroid nodules and cancers in children, Pediatr Endocrinol Rev 6:14–23, 2008.
Ly S, Frates MC, Benson CB, et al: Features and outcome of autonomous thyroid nodules in children: 31 consecutive patients seen at a single center, J Clin Endocrinol Metab 101(10):3856–3862, 2016.
Niedziela M: Pathogenesis, diagnosis and management of thyroid nodules in children, Endocr Relat Cancer 13:427–453, 2006.
Wiersinga WM: Management of thyroid nodules in children and adolescents, Hormones (Athens) 6:194–199, 2007.
Alkhairy OK, Abolhassani H, Rezaei N, et al: Spectrum of phenotypes associated with mutations in LRBA, J Clin Immunol 36(1):33–45, 2016.
Allenspach E, Torgerson TR: Autoimmunity and primary immunodeficiency disorders, J Clin Immunol 36(April):57–67, 2016.
American Diabetes Association: Standards of medical care in diabetes—2017, 12. Children and adolescents, Diabetes Care 40(Suppl 1):S105–S113, 2017.
Barclay SF, Rand CM, Borch LA, et al: Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD): exome sequencing of trios, monozygotic twins and tumours, Orphanet J Rare Dis 10(1):103, 2015.
Barzaghi F, Passerini L, Bacchetta R: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immunodeficiency with autoimmunity, Front Immunol 3(July):1–25, 2012.
Bin Dhuban K, Piccirillo CA: The immunological and genetic basis of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, Curr Opin Allergy Clin Immunol 15(6):525–532, 2015.
Bornstein SR, Allolio B, Arlt W, et al: Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline, J Clin Endocrinol Metab 101(2):364–389, 2016.
Bougnores P, Pantalone L, Linglart A, et al: Endocrine manifestations of the rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor syndrome in childhood, J Clin Endocrinol Metab 93(10):3971–3980, 2008.
Bruserud A, Oftedal BE, Landegren N, et al: A longitudinal follow-up of autoimmune polyendocrine syndrome type 1, J Clin Endocrinol Metab 101(8):2975–2983, 2016.
Byun DJ, Wolchok JD, Rosenberg LM, Girotra M: Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies, Nat Rev Endocrinol 2017.
Chow J, Rahman J, Achermann JC, et al: Mitochondrial disease and endocrine dysfunction, Nature 13:92–104, 2017.
Eisenbarth GS, Gottlieb PA: Autoimmune polyendocrine syndromes, N Engl J Med 350(20):2068–2079, 2004.
Ferre EMN, Rose SR, Rosenzweig SD, et al: Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, JCI Insight 1(13):1–18, 2016.
Hetemoki I, Jarva H, Kluger N, et al: Anticommensal responses are associated with regulatory T cell defect in autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy patients, J Immunol 196(7):2955–2964, 2016.
Husebye ES, Anderson MS: Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis, Immunity 32(4):479–487, 2010.
Husebye ES, Anderson MS, K?mpe O: Autoimmune polyendocrine syndromes, N Engl J Med 378(12):1132–1141, 2018.
Jorgensen KT, Rostgaard K, Bache I, et al: Autoimmune diseases in women with Turner’s syndrome, Arthritis Rheum 62(3):658–666, 2010.
Kanai T, Jenks J, Nadeau KC: The STAT5b pathway defect and autoimmunity, Front Immunol 3(Aug):1–8, 2012.
Kisand K, Peterson P: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: known and novel aspects of the syndrome, Ann N Y Acad Sci 1246(5):77–91, 2011.
Landegren N, Sharon D, Freyhult E, et al: Proteome-wide survey of the autoimmune target repertoire in autoimmune polyendocrine syndrome type 1, Sci Rep 6(February):20104, 2016.
Lleo A, Moroni L, Caliari L, Invernizzi P: Autoimmunity and Turner’s syndrome, Autoimmun Rev 11(6–7):A538–A543, 2012.
Lohr NJ, Molleston JP, Strauss KA, et al: Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease, Am J Hum Genet 86(3):447–453, 2010.
Mart?n MG, Lindberg I, Solorzano-Vargas S, et al: Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other encocrinopathies in a pediatric cohort, Gastroenterol 145:138–148, 2013.
Meloni A, Willcox N, Meager A, et al: Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients, J Clin Endocrinol Metab 97(4):1114–1124, 2012.
Meyer S, Woodward M, Hertel C, et al: AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies, Cell 166(3):582–595, 2016.
Nambam B, Winter WE, Schatz DA: Igg4 antibodies in autoimmune polyglandular disease and IgG4-related endocrinopathies: pathophysiology and clinical characteristics, Curr Opin Pediatr 26(4):493–499, 2014.
Sanaker PS, Husebye ES, Findenes O, et al: Clinical evolution of Kearns- Sayre syndrome with polyendocrioopathy and respiratory failure, Acta Neurol Scand 115(Suool 187):64–67, 2007.
Schaefer AM, Walker M, Turnbull DM, Taylor RW: Endocrine disorders in mitochondrial disease, Mol Cell Endocrinol 379:2–11, 2013.
Schubert D, Bode C, Kenefeck R, et al: Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations, Nat Med 20(12):1410–1416, 2014.
Seminog OO, Seminog AB, Yeates D, Goldacre MJ: Associations between Klinefelter’s syndrome and autoimmune diseases: English national record linkage studies, Autoimmunity 48(2):125–128, 2015.
Torino F, Barnabei A, Paragliola R, et al: Thyroid dysfunction as an unintended side effect of anticancer drugs, Thyroid 23(11):1345–1366, 2013.
van de Ven AAJM, Warnatz K: The autoimmune conundrum in common variable immunodeficiency disorders, Curr Opin Allergy Clin Immunol 15(6):514–524, 2015.
Verbsky JW, Chatila TA: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases, Curr Opin Pediatr 25(6):708–714, 2013.
Goncalves TD, Toledo RA, Sekiya T, et al: Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life, J Clin Endocrinol Metab 99:E89–E96, 2014.
Goudet P, Dalac A, Le Bras M, et al: MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’?tude des Tumeurs Endocrines, J Clin Endocrinol Metab 100:1568–1577, 2015.
Kollars J, Zarroug AE, van Heerden J, et al: Primary hyperparathyroidism in pediatric patients, Pediatrics 115:974–980, 2005.
Mallet E, Working Group on Calcium Metabolism: Primary hyperparathyroidism in neonates and childhood: the French experience (1984-2004), Horm Res 69:180–188, 2008.
Romero Arenas MA, Morris LF, Rich TA, et al: Preoperative multiple endocrine neoplasia type 1 diagnosis improves the surgical outcomes of pediatric patients with primary hyperparathyroidism, J Pediatr Surg 49:546–550, 2014.
Skinner MA, Moley JA, Dilley WG, et al: Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A, N Engl J Med 353:1105–1113, 2005.
Thakker RV, Newey PJ, Walls GV, et al: Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1), J Clin Endocrinol Metab 97:2990–3011, 2012.
Wells SA, Asa SL, Dralle H, et al: Revised American Thyroid Association guidelines for the management of medullary thyroid cancer, Thyroid 25:567–610, 2015.
Ardeshirpour L, Cole DE, Carpenter TO: Evaluation of bone and mineral disorders, Pediatr Endocrinol Rev 5(Suppl 1):584–598, 2007.
Canaff L, Zhou X, Mosesova I, et al: Glial cells missing-2 (GCM2) transactivates the calcium-sensing receptor gene: effect of a dominant-negative GCM2 mutant associated with autosomal dominant hypoparathyroidism, Hum Mutat 30(1):85–92, 2009.
Gattineni J: Inherited disorders of calcium and phosphate metabolism, Curr Opin Pediatr 26:215–222, 2014.
Mitchell DM, Juppner H: Regulation of calcium homeostasis and bone metabolism in the fetus and neonate, Curr Opin Endocrinol Diabetes Obes 17:25–30, 2010.
Mornet E: Hypophosphatasia: the mutations in the tissue-nonspecific alkaline phosphatase gene, Hum Mutat 15(4):309–315, 2000.
Stanley S, Shaw NJ: Is it my calcium, doctor?Arch Dis Child Educ Pract Ed 94:169–176, 2009.
Bowl MR, Nesbit MA, Harding B, et al: An interstitial deletion-insertion involving chromosome 2p25.3 and Xq27.1, near SOX3, causes X-linked recessive hypoparathyroidism, J Clin Invest 115(10):2822–2831, 2005.
Bilezikian JP, Brandi ML, Cusano NE, et al: Management of hypoparathyroidism: present and future, J Clin Endocrinol Metab 101:2313–2324, 2016.
Capalbo D, Improda N, Esposito A, et al: Autoimmune polyendocrinopathy-candidiasis ectodermal dystrophy from the pediatric perspective, J Endocrinol Invest 36:903–912, 2013.
Cho YH, Tchan M, Roy B, et al: Recombinant parathyroid hormone therapy for severe neonatal hypoparathyroidism, J Pediatr 160:345–348, 2012.
Ding C, Buckingham B, Levine M: Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB, J Clin Invest 108:1215–1220, 2001.
Gavalas NG, Kemp EH, Krohn KJ, et al: The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1, J Clin Endocrinol Metab 92(6):2107–2114, 2007.
Goodwin G, Hawley PP, Miller DT: A case of HDR syndrome and ichthyosis: dual diagnosis by whole-genome sequencing of novel mutations in GATA3 and STS genes, J Clin Endocrinol Metab 101(3):837–840, 2016
Kahn KT, Uma R, Farag TI, et al: Kenny-Caffey syndrome in six Bedouin sibships: autosomal recessive inheritance is confirmed, Am J Med Genet 69:126–132, 1997.
Li D, Streeten EA, Chan A, et al: Exome sequencing reveals mutations in AIRE as a cause of isolated hypoparathyroidism, J Clin Endocrinol Metab 102(5):1726–1733, 2017.
Oskarsdottir S, Persson C, Eriksson BO, et al: Presenting phenotype in 100 children with the 22q11 deletion syndrome, Eur J Pediatr 164(3):146–153, 2005.
Parvari R, Hershkovitz F, Grossman N, et al: Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome, Nat Genet 32:448–452, 2002.
Winer KK, Fulton KA, Albert PS, Cutler GB Jr: Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1–34 in children with severe congenital hypoparathyroidism, J Pediatr 165:556–563, 2014.
Yagi H, Furutani Y, Hamada H, et al: Role of TBX1 in human del22q11.2 syndrome, Lancet 362(9393):1366–1373, 2003.
Brix B, Werner R, Staedt P, et al: Different pattern of epigenetic changes of the GNAS gene Locus in patients with PHP1C confirm heterogeneity of underlying pathomechanisms in the Subgroup of PHP and a demand for a new classification of GNAS-related Disorders, J Clin Endocrinol Metab 99(8):E1564–E1570, 2014.
Linglart A, Menguy C, Couvineau A, et al: Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance, N Engl J Med 364:2218–2226, 2011.
Lynch DC, Dyment DA, Huang L, et al: Identification of novel mutations confirms Pde4d as a major gene causing acrodysostosis, Hum Mutat 34:97–102, 2013.
Mantovani G, Bondioni S, Linglart A, et al: Genetic analysis and evaluation of resistance to thyrotropin and growth hormone-releasing hormone in pseudohypoparathyroidism type 1b, J Clin Endocrinol Metab 92(9):3738–3742, 2007.
Mitsu T, Kim OH, Hall CM, et al: Acroscyphodysplasia as a phenotypic variation of pseudohypoparathyroidis and acrodysostosis type 2, Am J Med Genet 164A(10):2529–2534, 2014.
Ritter C, Gobel CH, Liebig T, et al: An epigenetic cause of seizures and brain calcification: pseudohypoparathyroidism, Lancet 385:1802–1803, 2015.
Simpson C, Grove E, Houston BA: Pseudopseudohypoparathyroidism, Lancet 385:1123, 2015.
Alos N, Eugene D, Fillion M, et al: Pamidronate: treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis, Horm Res 65(6):289–294, 2006.
Carpten JD, Robbins CM, Villablanca A, et al: HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndrome, Nat Genet 32(4):676–680, 2002.
Domico MB, Huynh V, Anand SK, et al: Severe hyperphosphatemia and hypocalcemic tetany after oral laxative administration in a 3-month-old infant, Pediatrics 118(5):e1580–e1583, 2006.
Goudet P, Dalac A, LeBras M, et al: MEN1 disease occurring before 21 years old: a 160-patient chohort study from the Groupe d’etude des Tumeurs Endocrines, J Clin Endocrinol Metab 100(4):1568–1577, 2015.
Kollars J, Zarroug AE, van Heerden J, et al: Primary hyperparathyroidism in pediatric patients, Pediatrics 115:974–980, 2005.
Letavernier E, Rodenas A, Guerrot D, et al: Williams-Beuren syndrome hypercalcemia: Is TRPC3 a novel mediator in calcium homeostasis? Pediatrics 129:e1626–e1630, 2012.
Lietman SA, Germain-Lee EL, Levine MA: Hypercalcemia in children and adolescents, Curr Opin Pediatr 22:508–515, 2010.
Marcocci C, Cetani F: Primary hyperparathyroidism, N Engl J Med 365:2389–2396, 2011.
Nesbit MA, Hannan FM, Howles SA, et al: Mutations affecting G-protein subunit ? in hypercalcemia and hypocalcemia, N Engl J Med 368:2476–2486, 2013.
Obermannova B, Banghova K, Sumnik Z, et al: Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene, Eur J Pediatr 168(5):569–591, 2009.
Pallan S, Rahman MO, Khan AA: Diagnosis and management of primary hyperparathyroidism, BMJ 344:55–60, 2012.
Schlingmann KP, Kaufmann M, Weber S, et al: Mutations in the CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 365:410–421, 2011.
Stokes VJ, Nielsen MF, Hannan FM, Thaller RV: Hypercalcemic disorders in children. J Bone Miner Res 32(11):2157–2170, 2017.
Ferraz-de-Souza B, Achermann JC: Disorders of adrenal development, Endocr Dev 13:19–32, 2008.
Haase M, Willenberg HS, Bornstein SR: Update on the corticomedullary interaction in the adrenal gland, Endocr Dev 20:28–37, 2011.
Kempna P, Fluck CE: Adrenal gland development and defects, Best Pract Res Clin Endocrinol Metab 22:77–93, 2008.
Kim AC, Barlaskar FM, Heaton JH, et al: In search of adrenocortical stem and progenitor cells, Endocr Rev 30:241–263, 2009.
Lourenco D, Brauner R, Lin L, et al: Mutations in NR5A1 associated with ovarian insufficiency, N Engl J Med 360:1200–1210, 2009.
Connelly MA: SR-BI-mediated HDL cholesteryl ester delivery in the adrenal gland, Mol Cell Endocrinol 300:83–88, 2009.
Goto M, Piper Hanley K, Marcos J, et al: In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development, J Clin Invest 116:953–960, 2006.
Miller WL, Auchus RJ: The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders, Endocr Rev 32:81–151, 2011.
White PC: Ontogeny of adrenal steroid biosynthesis: why girls will be girls, J Clin Invest 116:872–874, 2006.
Guagliardo NA, Yao J, Hu C, et al: Minireview: aldosterone biosynthesis: electrically gated for our protection, Endocrinology 153:3579–3586, 2012.
Hattangady NG, Olala LO, Bollag WB, et al: Acute and chronic regulation of aldosterone production, Mol Cell Endocrinol 350:151–162, 2012.
Miller WL, Auchus RJ: The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders, Endocr Rev 32:81–151, 2011.
Nakamura Y, Gang HX, Suzuki T, et al: Adrenal changes associated with adrenarche, Rev Endocr Metab Disord 10:19–26, 2009.
Novoselova TV, Jackson D, Campbell DC, et al: Melanocortin receptor accessory proteins in adrenal gland physiology and beyond, J Endocrinol 217:R1–R11, 2013.
Rege J, Rainey WE: The steroid metabolome of adrenarche, J Endocrinol 214:133–143, 2012.
Baschant U, Lane NE, Tuckermann J: The multiple facets of glucocorticoid action in rheumatoid arthritis, Nat Rev Rheumatol 8:645–655, 2012.
Fuller PJ, Yao Y, Yang J, et al: Mechanisms of ligand specificity of the mineralocorticoid receptor, J Endocrinol 213:15–24, 2012.
Glass CK, Saijo K: Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells, Nat Rev Immunol 10:365–376, 2010.
Joels M, Sarabdjitsingh RA, Karst H: Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes, Pharmacol Rev 64:901–938, 2012.
Kim HJ: New understanding of glucocorticoid action in bone cells, BMB Rep 43:524–529, 2010.
Kuo T, Harris CA, Wang JC: Metabolic functions of glucocorticoid receptor in skeletal muscle, Mol Cell Endocrinol 380(1–2):79–88, 2013.
Reid DM, Devogelaer J-P, Saag K, et al; and for the HORIZON investigators: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, Lancet 373:1253–1263, 2009.
Tahrani AA, Bailey CJ, Del PS, et al: Management of type 2 diabetes: new and future developments in treatment, Lancet 378:182–197, 2011.
van Raalte DH, Ouwens DM, Diamant M: Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?, Eur J Clin Invest 39:81–93, 2009.
Vandevyver S, Dejager L, Tuckermann J, et al: New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation, Endocrinology 154:993–1007, 2013.
Wendler A, Albrecht C, Wehling M: Nongenomic actions of aldosterone and progesterone revisited, Steroids 77:1002–1006, 2012.
Adams MS, Bronner-Fraser M: Review: the role of neural crest cells in the endocrine system, Endocr Pathol 20:92–100, 2009.
Eisenhofer G, Kopin IJ, Goldstein DS: Catecholamine metabolism: a contemporary view with implications for physiology and medicine, Pharmacol Rev 56:331–349, 2004.
Goldstein DS, Kopin IJ: Adrenomedullary, adrenocortical, and sympathoneural responses to stressors: a meta-analysis, Endocr Regul 42:111–119, 2008.
Afroze B, Amjad N, Ibrahim SH, et al: Adrenal insufficiency in a child with MELAS syndrome, Brain Dev 36:924–927, 2014.
Akirav EM, Ruddle NH, Herold KC: The role of AIRE in human autoimmune disease, Nat Rev Endocrinol 7:25–33, 2011.
Bornstein SR: Predisposing factors for adrenal insufficiency, N Engl J Med 360:2328–2339, 2009.
Bornstein SR, Allolio B, Arlt W, et al: Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab 101:364–389, 2016.
Calderwood L, Holm IA, Teot LA, Anselm I: Adrenal insufficiency in mitochondrial disease: a rare case of GFER-related mitochondrial encephalomyopathy and review of the literature, J Child Neurol 31(2):190–194, 2016.
Chung TT, Chan LF, Metherell LA, et al: Phenotypic characteristics of familial glucocorticoid deficiency (FGD) type 1 and 2, Clin Endocrinol (Oxf) 72:589–594, 2010.
Debono M, Ghobadi C, Rostami-Hodjegan A, et al: Modified-release hydrocortisone to provide circadian cortisol profiles, J Clin Endocrinol Metab 94:1548–1554, 2009.
Ferraz-de-Souza B, Achermann JC: Disorders of adrenal development, Endocr Dev 13:19–32, 2008.
Hannah-Shmouni F, Demidowich A, Stratakis CA: Cortisol in the evaluation of adrenal insufficiency, JAMA 316(5):535–536, 2016.
Hsieh S, White PC: Presentation of primary adrenal insufficiency in childhood, J Clin Endocrinol Metab 96:E925–E928, 2011.
Hughes CR, Guasti L, Meimaridou E, et al: MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans, J Clin Invest 122:814–820, 2012.
Llano JP, Beaufils E, Nicolino M: Uncommon cause of large paravertebral calcification in a child, J Pediatr 162:881, 2013.
Logan CV, Murray JE, Parry DA, et al: DNA polymerase epsilon deficiency causes IMAGe syndrome with variable immunodeficiency, Am J Hum Genet 103:1038–1044, 2018.
Meimaridou E, Kowalczyk J, Guasti L, et al: Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency, Nat Genet 44:740–742, 2012.
Michels A, Michels N: Addison disease: early detection and treatment principles, Am Fam Physician 89:563–568, 2014.
Neto RAB, Freire de Carvalho J: Diagnosis and classification of Addison’s disease (autoimmune adrenalitis), Autoimmune Rev 13:408–411, 2014.
Perlman SJ, Mar S: Leukodystrophies, Adv Exp Med Biol 724:154–171, 2012.
Schimmer BP, White PC: Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease, Mol Endocrinol 24:1322–1337, 2010.
Shulman DI, Palmert MR, Kemp SF: Adrenal insufficiency: still a cause of morbidity and death in childhood, Pediatrics 119:e484–e494, 2007.
Wass JAH, Arlt W: How to avoid precipitating an acute adrenal crisis, BMJ 345:9, 2012.
Ahmad T, Borchert M, Geffner M: Optic nerve hypoplasia and hypopituitarism, Pediatr Endocrinol Rev 5:772–777, 2008.
Ahmet A, Brienza V, Tran A, et al: Frequency and duration of adrenal suppression following glucocorticoid theryapy in children with rheumatic diseases, Arthritis Care Res 69(8):1224–1230, 2017.
de Lind van Wijngaarden RF, Joosten KF, van den Berg S, et al: The relationship between central adrenal insufficiency and sleep-related breathing disorders in children with Prader-Willi syndrome, J Clin Endocrinol Metab 94:2387–2393, 2009.
Gordijn MS, Rensen N, Gemke RJ, et al: Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia, Cochrane Database Syst Rev (8):CD008727, 2015.
Grugni G, Beccaria L, Corrias A, et al: Central adrenal insufficiency in young adults with Prader-Willi Syndrome, Clin Endocrinol (Oxf) 79(3):371–378, 2013.
Hsu AA, von Elten K, Chan D, et al: Characterization of the cortisol stress response to sedation and anesthesia in children, J Clin Endocrinol Metab 97:E1830–E1835, 2012.
Kazlauskaite R, Evans AT, Villabona CV, et al: Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis, J Clin Endocrinol Metab 93:4245–4253, 2008.
Kelberman D, Dattani MT: Role of transcription factors in midline central nervous system and pituitary defects, Endocr Dev 14:67–82, 2009.
Zollner EW: Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids (Part 2)—the risk as determined by gold standard adrenal function tests: a systematic review, Pediatr Allergy Immunol 18:469–474, 2007.
Aneja R, Carcillo JA: What is the rationale for hydrocortisone treatment in children with infection-related adrenal insufficiency and septic shock?, Arch Dis Child 92:165–169, 2007.
Brierley J, Carcillo JA, Choong K, et al: Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine, Crit Care Med 37:666–688, 2009.
Hebbar KB, Stockwell JA, Leong T, et al: Incidence of adrenal insufficiency and impact of corticosteroid supplementation in critically ill children with systemic inflammatory syndrome and vasopressor-dependent shock, Crit Care Med 39:1145–1150, 2011.
Lundy JB, Slane ML, Frizzi JD: Acute adrenal insufficiency after a single dose of etomidate, J Intensive Care Med 22:111–117, 2007.
Pizarro CF, Troster EJ, Damiani D, et al: Absolute and relative adrenal insufficiency in children with septic shock, Crit Care Med 33:855–859, 2005.
Charmandari E, Kino T, Chrousos GP: Primary generalized familial and sporadic glucocorticoid resistance (Chrousos syndrome) and hypersensitivity, Endocr Dev 24:67–85, 2013.
van Rossum EF, Lamberts SW: Glucocorticoid resistance syndrome: a diagnostic and therapeutic approach, Best Pract Res Clin Endocrinol Metab 20:611–626, 2006.
Lavery GG, Walker EA, Tiganescu A, et al: Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency, J Clin Endocrinol Metab 93:3827–3832, 2008.
Lawson AJ, Walker EA, Lavery GG, et al: Cortisone-reductase deficiency associated with heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1, Proc Natl Acad Sci USA 108:4111–4116, 2011.
White PC, Rogoff D, McMillan DR: Physiological roles of 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase, Curr Opin Pediatr 20:453–457, 2008.
Boyden LM, Choi M, Choate KA, et al: Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities, Nature 482:98–102, 2012.
Fernandes-Rosa FL, Hubert EL, Fagart J, et al: Mineralocorticoid receptor mutations differentially affect individual gene expression profiles in pseudohypoaldosteronism type 1, J Clin Endocrinol Metab 96:E519–E527, 2011.
Hubert EL, Teissier R, Fernandes-Rosa FL, et al: Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1, J Am Soc Nephrol 22:1997–2003, 2011.
Zennaro MC, Hubert EL, Fernandes-Rosa FL: Aldosterone resistance: structural and functional considerations and new perspectives, Mol Cell Endocrinol 350:206–215, 2012.
Chapman K, Holmes M, Seckl J: 11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action, Physiol Rev 93:1139–1206, 2013.
Hassan-Smith Z, Stewart PM: Inherited forms of mineralocorticoid hypertension, Curr Opin Endocrinol Diabetes Obes 18:177–185, 2011.
Ellison DH: Ubiquitylation and the pathogenesis of hypertension, J Clin Invest 123:546–548, 2013.
DiSandro M, Merke DP, Rink RC: Review of current surgical techniques and medical management considerations in the treatment of pediatric patients with disorders of sex development, Horm Metab Res 47:321–328, 2015.
Finkielstain GP, Chen W, Mehta SP, et al: Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, J Clin Endocrinol Metab 96:E161–E172, 2011.
Finkielstain GP, Kim MS, Sinaii N, et al: Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia, J Clin Endocrinol Metab 97:4429–4438, 2012.
Gidlof S, Falhammar H, Thilin A, et al: One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study, Lancet 1:35–42, 2013.
Gidlof S, Wedell A, Guthenberg C, et al: Nationwide neonatal screening for congenital adrenal hyperplasia in Sweden, JAMA Pediatrics 168:567, 2014.
Mallappa A, Sinaii N, Kumar P, et al: A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia, J Clin Endocrinol Metab 100:1137–1145, 2015.
Merce Fernandez-Balsells M, Muthusamy K, Smushkin G, et al: Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21-hydroxylase (CYP21A2) deficiency: a systematic review and meta-analyses, Clin Endocrinol (Oxf) 73:436–444, 2010.
Meyer-Bahlburg HF, Dolezal C, Baker SW, et al: Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess, Arch Sex Behav 37:85–99, 2008.
Minette MS, Hoyer AW, Pham PP, et al: Cardiac function in congenital adrenal hyperplasia: a pattern of reversible cardiomyopathy, J Pediatr 162:1193–1198, 2013.
Muthusamy K, Elamin MB, Smushkin G, et al: Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis, J Clin Endocrinol Metab 95:4161–4172, 2010.
Nella AA, Mallappa A, Perritt AF, et al: A phase 2 study of continuous subcutaneous hydrocortisone infusion in adults with congenital adrenal hyperplasia, J Clin Endocrinol Metab 101:4690–4698, 2016.
Nordenstrom A, Frisen L, Falhammar H, et al: Sexual function and surgical outcome in women with congenital adrenal hyperplasia due to CYP21A2 deficiency: clinical perspective and the patients’ perception, J Clin Endocrinol Metab 95:3633–3640, 2010.
Speiser PW, Arlt W, Auchus RJ, et al: Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab 103(11):4043–4088, 2018.
White P: Update on diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency, Curr Opin Endocrinol Diabetes Obes 25:178–184, 2018.
White PC: Neonatal screening for congenital adrenal hyperplasia, Nat Rev Endocrinol 5:490–498, 2009.
Yang M, White PC: Risk factors for hospitalization of children with congenital adrenal hyperplasia, Clin Endocrinol (Oxf) 86(5):669–673, 2017.
White PC: Steroid 11 beta-hydroxylase deficiency and related disorders, Endocrinol Metab Clin North Am 30:61–79, 2001.
Zhao LQ, Han S, Tian HM: Progress in molecular-genetic studies on congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency, World J Pediatr 4:85–90, 2008.
Simard J, Ricketts ML, Gingras S, et al: Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family, Endocr Rev 26:525–582, 2005.
Auchus RJ: The backdoor pathway to dihydrotestosterone, Trends Endocrinol Metab 15:432–438, 2004.
Idkowiak J, Randell T, Dhir V, et al: A missense mutation in the human cytochrome b5 gene causes 46,XY disorder of sex development due to true isolated 17,20 lyase deficiency, J Clin Endocrinol Metab 97:E465–E475, 2012.
Krone N, Arlt W: Genetics of congenital adrenal hyperplasia, Best Pract Res Clin Endocrinol Metab 23:181–192, 2009.
Miller WL: The syndrome of 17,20 lyase deficiency, J Clin Endocrinol Metab 97:59–67, 2012.
Miller WL: StAR search—what we know about how the steroidogenic acute regulatory protein mediates mitochondrial cholesterol import, Mol Endocrinol 21:589–601, 2007.
Stocco DM: Clinical disorders associated with abnormal cholesterol transport: mutations in the steroidogenic acute regulatory protein, Mol Cell Endocrinol 191:19–25, 2002.
Tee MK, Abramsohn M, Loewenthal N, et al: Varied clinical presentations of seven patients with mutations in CYP11A1 encoding the cholesterol side-chain cleavage enzyme, P450scc, J Clin Endocrinol Metab 98:713–720, 2013.
Krone N, Reisch N, Idkowiak J, et al: Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency, J Clin Endocrinol Metab 97:E257–E267, 2012.
Miller WL, Agrawal V, Sandee D, et al: Consequences of POR mutations and polymorphisms, Mol Cell Endocrinol 336:174–179, 2011.
Schmidt K, Hughes C, Chudek JA, et al: Cholesterol metabolism: the main pathway acting downstream of cytochrome P450 oxidoreductase in skeletal development of the limb, Mol Cell Biol 29:2716–2729, 2009.
Leshinsky-Silver E, Landau Z, Unlubay S, et al: Congenital hyperreninemic hypoaldosteronism in Israel: sequence analysis of CYP11B2 gene, Horm Res 66:73–78, 2006.
Nguyen HH, Hannemann F, Hartmann MF, et al: Five novel mutations in CYP11B2 gene detected in patients with aldosterone synthase deficiency type I: functional characterization and structural analyses, Mol Genet Metab 100:357–364, 2010.
White PC: Aldosterone synthase deficiency and related disorders, Mol Cell Endocrinol 217:81–87, 2004.
Halperin F, Dluhy RG: Glucocorticoid-remediable aldosteronism, Endocrinol Metab Clin North Am 40:333–341, viii, 2011.
Almeida MQ, Soares IC, Ribeiro TC, et al: Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults, J Clin Endocrinol Metab 95:1458–1462, 2010.
Custodio G, Parise GA, Kiesel FN, et al: Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors, J Clin Oncol 31:2619–2626, 2013.
Else T, Kim AC, Sabolch A, et al: Adrenocortical carcinoma, Endocr Rev 35:282–326, 2014.
Faria AM, Almeida MQ: Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults, Mol Cell Endocrinol 351:52–57, 2012.
Heloury Y, Muthucumaru M, Panabokke G, et al: Minimally invasive adrenalectomy in children, J Pediatr Surg 47:415–421, 2012.
McAteer JP, Huaco JA, Gow KW: Predictors of survival in pediatric adrenocortical carcinoma: a surveillance, epidemiology, and end results (SEER) program study, J Pediatr Surg 48:1025–1031, 2013.
Mulatero P, Monticone S, Rainey WE, et al: Role of KCNJ5 in familial and sporadic primary aldosteronism, Nat Rev Endocrinol 9:104–112, 2013.
Nakamura Y, Yamazaki Y, Felizola SJ, et al: Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis, Endocrinol Metab Clin North Am 44:399–410, 2015.
Nieman LK: Approach to the patient with an adrenal incidentaloma, J Clin Endocrinol Metab 95:4106–4113, 2010.
Raymond VM, Else T, Everett JN, et al: Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma, J Clin Endocrinol Metab 98:E119–E125, 2013.
Redlich A, Boxberger N, Strugala D, et al: Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial, Klin Padiatr 224:366–371, 2012.
Ribeiro RC, Pinto EM, Zambetti GP: Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies, Best Pract Res Clin Endocrinol Metab 24:477–490, 2010.
Su K, Donaldson E, Sharma R: Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa, Appl Clin Genet 9:157–167, 2016. eCollection;%2016.: 157-167.
Zeiger MA, Siegelman SS, Hamrahian AH: Medical and surgical evaluation and treatment of adrenal incidentalomas, J Clin Endocrinol Metab 96:2004–2015, 2011.
Else T, Kim AC, Sabolch A, et al: Adrenocortical carcinoma, Endocr Rev 35:282–326, 2014.
Nakamura Y, Yamazaki Y, Felizola SJ, et al: Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis, Endocrinol Metab Clin North Am 44:399–410, 2015.
Raymond VM, Else T, Everett JN, et al: Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma, J Clin Endocrinol Metab 98:E119–E125, 2013.
Ribeiro RC, Pinto EM, Zambetti GP: Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies, Best Pract Res Clin Endocrinol Metab 24:477–490, 2010.
Batista DL, Riar J, Keil M, et al: Diagnostic tests for children who are referred for the investigation of Cushing syndrome, Pediatrics 120:e575–e586, 2007.
Beuschlein F, Fassnacht M, Assi? G, et al: Constitutive activation of PKA a catalytic subunit in adrenal Cushing’s syndrome, N Engl J Med 370:1019–1028, 2014.
Colao A, Petersenn S, Newell-Price J, et al: A 12-month phase 3 study of pasireotide in Cushing’s disease, N Engl J Med 366:914–924, 2012.
Keil MF: Quality of life and other outcomes in children treated for Cushing syndrome, J Clin Endocrinol Metab 98:2667–2678, 2013.
Lacroix A, Feelders RA, Stratakis CA, et al: Cushing’s syndrome, Lancet 386:913–927, 2015.
Lodish M, Stratakis CA: A genetic and molecular update on adrenocortical causes of Cushing syndrome, Nat Rev Endocrinol 12:255–262, 2016.
Lodish M, Dunn SV, Sinaii N, et al: Recovery of the hypothalamic-pituitary-adrenal axis in children and adolescents after surgical cure of Cushing’s disease, J Clin Endocrinol Metab 97:1483–1491, 2012.
Loriaux DL: Diagnosis and differential diagnosis of Cushing’s syndrome, N Engl J Med 367(15):1451–1459, 2017.
More J, Young J, Reznik Y, et al: Ectopic ACTH syndrome in children and adolescents, J Clin Endocrinol Metab 96:1213–1222, 2011.
Nieman LK, Biller BM, Findling JW, et al: The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab 93:1526–1540, 2008.
Choi M, Scholl UI, Yue P, et al: K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension, Science 331:768–772, 2011.
Funder JW, Carey RM, Mantero F, et al: The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab 101:1889–1916, 2016.
Li JS, Flynn JT, Portman R, et al: The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study, J Pediatr 157:282–287, 2010.
Mattsson C, Young WF Jr: Primary aldosteronism: diagnostic and treatment strategies, Nat Clin Pract Nephrol 2:198–208, 2006.
Mulatero P, Monticone S, Rainey WE, et al: Role of KCNJ5 in familial and sporadic primary aldosteronism, Nat Rev Endocrinol 9:104–112, 2013.
Stowasser M, Pimenta E, Gordon RD: Familial or genetic primary aldosteronism and Gordon syndrome, Endocrinol Metab Clin North Am 40:343–368, viii, 2011.
Vaidya A, Hamrahian AH, Auchus RJ: Genetics of primary aldosteronism, Endocr Pract 21(4):400–405, 2015.
Ayala-Ramirez M, Feng L, Johnson MM, et al: Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators, J Clin Endocrinol Metab 96:717–725, 2011.
Chen H, Sippel RS, O’Dorisio MS, et al: The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer, Pancreas 39:775–783, 2010.
Derlin T, Busch JD, Wisotzki C, et al: Intraindividual comparison of 123I-mIBG SPECT/MRI, 123I-mIBG SPECT/CT, and MRI for the detection of adrenal pheochromocytoma in patients with elevated urine or plasma catecholamines, Clin Nucl Med 38(1):e1–e6, 2013.
Ayala-Ramirez M, Feng L, Johnson MM, et al: Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators, J Clin Endocrinol Metab 96:717–725, 2011.
Chen H, Sippel RS, O’Dorisio MS, et al: The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer, Pancreas 39:775–783, 2010.
Derlin T, Busch JD, Wisotzki C, et al: Intraindividual comparison of 123I-mIBG SPECT/MRI, 123I-mIBG SPECT/CT, and MRI for the detection of adrenal pheochromocytoma in patients with elevated urine or plasma catecholamines, Clin Nucl Med 38(1):e1–e6, 2013.
Fishbein L, Nathanson KL: Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background, Cancer Genet 205:1–11, 2012.
Pacak K, Eisenhofer G, Ahlman H, et al: Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005, Nat Clin Pract Endocrinol Metab 3:92–102, 2007.
Taieb D, Pacal K: New insights into nuclear imaging phenotypes of cluster 1 pheochromocytoma and paraganglioma, Trends Endocrinol Metab 28(11):807–817, 2017.
Turkova H, Prodanov T, Maly M, et al: Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma/paraganglioma: an National Institutes of Health study, Endocr Pract 22:302–314, 2016.
Waguespack SG, Rich T, Grubbs E, et al: A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma, J Clin Endocrinol Metab 95:2023–2037, 2010.
Weingarten TN, Cata JP, O’Hara JF, et al: Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma, Urology 76:508–511, 2010.
Yang M, Soga T, Pollard PJ: Oncometabolites: linking altered metabolism with cancer, J Clin Invest 123:3652–3658, 2013.
Baxter RM, Arboleda VA, Lee H et al. Exome sequencing for the diagnosis of 46,XY disorders of sex development. J Clin Endocrinol Metab. 2015;100:e333–e344.
Bergada I, Bergada C, Campo S. Role of inhibins in childhood and puberty. J Pediatr Endocrinol Metab. 2001;14:343–353.
Bouvattier C, Carel JC, Lecointre C et al. Postnatal changes of T, LH, and FSH in 46,XY infants with mutations in the AR gene. J Pediatr Endocrinol Metab. 2002;87:29–32.
Fluck CE, Meyer-Boni M, Pandley AV et al. Why males will be males: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am J Hum Genet. 2011;89:201–218.
Habert R, Lejeune H, Saez J. Origin, differentiation and regulation of fetal and adult Leydig cells. Mol Cell Endocrinol. 2001;179:47–74.
Harrington J, Palmert MR. Distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism: critical appraisal of available diagnostic tests. J Clin Endocrinol Metab. 2012;97:3056–3067.
Hughes IA. Female development — all by default? N Engl J Med. 2004;351:748–750.
Josso N, diClemente N, Gouedard L. Anti-m?llerian hormone and its receptors. Mol Cell Endocrinol. 2001;179:25–32.
Lee PA, Houk CP, Ahmed SF et al. International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics. 2006;118:e488–e500.
Quigley CA. The postnatal gonadotropin and sex steroid surge: insights from the androgen insensitivity syndrome [editorial]. J Clin Endocrinol Metab. 2002;87:24–28.
Rajpert-De Meyts E. Expression of anti-M?llerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999;84:3836–3844.
Rey RA, Belville C, Nihoul-F?k?t? C et al. Evaluation of gonadal function in 107 intersex patients by means of serum anti-m?llerian hormone measurements. J Clin Endocrinol Metab. 1999;84:627–631.
Sequera AM, Fideleff HL, Boquete HR et al. Basal ultra sensitive LH assay: a useful tool in the early diagnosis of male pubertal delay? J Pediatr Endocrinol Metab. 2002;15:589–596.
She Z-Y, Yang W-X. Molecular mechanisms involved in mammalian primary sex determination. J Mol Endocrinol. 2014;53:R21–R37.
Stenvers KL, Findlay JK. Inhibins: from reproductive hormones to tumor suppressors. Trends Endocrinol Metab. 2010;21:174–180.
Swerdloff RS, Wang C, Cunningham G et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85:4500–4510.
Teixeira J, Maheswaran S, Donahue PK. M?llerian inhibiting substance: an instructive development hormone with diagnostic and possible therapeutic applications. Endocr Rev. 2001;22:657–674.
Tomaselli S, Megiorni F, Lin L et al. Human RSPO1/R-spondin1is expressed during early ovary development and augments ?-catenin signaling. PLoS ONE. 2011;6:e16366.
Aoki Y, Niihori T, Inoue S, Matsubara Y: Recent advances in RA Sopathies, J Hum Genet 61(1):33–39, 2016. doi:10.1038/jhg.2015.114. PMID: 26446362. Review.
Bonde JP, Flachs EM, Rimborg S, et al: The epidemiologic evidence linking prenatal and postnatal exposure to endocrine disrupting chemicals with male reproductive disorders: a systematic review and meta-analysis, Hum Reprod Update 23(1):104–125, 2016.
Groth KA, Skakkeb?k A, Host C, et al: Clinical review: Klinefelter syndrome—a clinical update, J Clin Endocrinol Metab 98(1):20–30, 2013.
Howell SJ, Shalet SM: Spermatogenesis after cancer treatment: damage and recovery, J Natl Cancer Inst Monogr 34:12–17, 2005.
Radmayr Christian, Dogan Hasan S., Hoebeke Piet, et al: Management of undescended testes: European Association of Urology/European Society for Paediatric Urology Guidelines, J Pediatr Urol 12(6):335–343, 2016. doi:10.1016/j.jpurol.2016.07.014.
Pirgon A, Dondar BN: Vanishing testes: a literature review, J Clin Res Pediatr Endocrinol 4(3):116–120, 2012.
Radmayr C, Dogan HS, Hoebeke P, et al: The feasibility of fertility preservation in adolescents with Klinefelter syndrome, Hum Reprod 28(6):1468–1479, 2013.
Wohlfahrt-Veje C, Main KM, Skakkebaek NE: Testicular dysgenesis syndrome: foetal origin of adult reproductive problems, Clin Endocrinol (Oxf) 71(4):459–465, 2009.
Boehm U, Bouloux PM, Dattani MT, et al: European consensus statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment, Nat Rev 11:547–564, 2015.
Raivio T, Falardeau J, Dwyer A, et al: Reversal of idiopathic hypogonadotropic hypogonadism, N Engl J Med 357:863–872, 2007.
Smith N, Quinton R: Kallmann syndrome, BMJ 346:36–37, 2013.
Topaloglu AK, Kotan LD: Genetics of hypogonadotropic hypogonadism, Endocr Dev 29:36–49, 2016. doi:10.1159/000438841. Review.
Wei C, Davis N, Honour J, Crowne E: The investigation of children and adolescents with abnormalities of pubertal timing, Ann Clin Biochem 54(1):20–32, 2017. doi:10.1177/0004563216668378. Review.
Young J: Approach to the male patient with congenital hypogonadotropic hypogonadism, J Clin Endocrinol Metab 97(3):707–718, 2012.
Zacharin M: Pubertal induction in hypogonadism: current approaches including use of gonadotrophins, Best Pract Res Clin Endocrinol Metab 29(3):367–383, 2015. doi:10.1016/j.beem.2015.01.002. PMID: 26051297. Review.
Gourgari E, Saloustros E, Stratakis CA: Large-cell calcifying Sertoli cell tumors of the testes in pediatrics, Curr Opin Pediatr 24(4):518–522, 2012.
Idrees MT, Ulbright TM, Oliva E, et al: Members of the International Society of Urological Pathology Testicular Tumour Panel. The World Health Organization 2016 classification of testicular non-germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel, Histopathology 70(4):513–521, 2017. doi:10.1111/his.13115. Review.
Kim MS, Goodarzian F, Keenan MF, et al: Testicular adrenal rest tumors in boys and young adults with congenital adrenal hyperplasia, J Urol 197(3 Pt 2):931–936, 2017. doi:10.1016/j.juro.2016.09.072.
Mameli C, Selvaggio G, Cerini C, et al: Atypical Leydig cell tumor in children: report of 2 cases, Pediatrics 138(5):2016
Olivier P, Simoneau-Roy J, Francoeur D, et al: Leydig cell tumors in children: contrasting clinical, hormonal, anatomical, and molecular characteristics in boys and girls, J Pediatr 161(6):1147–1152, 2012.
Osbun N, Winters B, Holt SK, et al: Characteristics of patients with Sertoli and Leydig cell testis neoplasms from a national population-based registry, Clin Genitourin Cancer 2016. doi:10.1016/j.clgc.2016.08.001. pii: S1558-7673(16)30235-X.
Atabek ME. Gynecomastia in puberty is usually asymptomatic and regresses spontaneously. J Pediatr Endocrinol Metab. 2013;26(5–6):605.
Dickson G. Gynecomastia. Am Fam Physician. 2012;85(7):716–722.
Lawrence SE, Faught KA, Vethamuthu J et al. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr. 2004;145:71–76.
Sansone A, Romanelli F, Sansone M et al. Gynecomastia and hormones. Endocrine. 2017;55(1):37–44. doi:10.1007/s12020-016-0975-9.
Stratakis CA, Vottero A, Brodies A et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab. 1998;83:1348–1357.
Betterle C, Volpato M. Adrenal and ovarian autoimmunity. Eur J Endocrinol. 1998;138:16–25.
Bondy CA. Care of females and women with Turner syndrome: a guideline of the Turner syndrome study group. J Clin Endocrinol Metab. 2007;92:10–25.
Calvo RM, Asuncion M, Telleria D et al. Screening for mutations in the steroidogenic acute regulatory protein and steroidogenic factor-1 genes, and in CYP11A and dosage-sensitive sex reversal-adrenal hypoplasia gene on the X chromosome, gene-1 (DAX-1), in hyperandrogenic hirsute women. J Clin Endocrinol Metab. 2001;86:1746–1749.
Carel JC, Mathivon L, Gendrel C et al. Near normalization of final height with adapted doses of growth hormone in Turner syndrome. J Clin Endocrinol Metab. 1998;83:1462–1466.
Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol. 2013;70:309–316.
Committee on Gynecologic Practice. Hormone therapy in primary ovarian insufficiency. Obstet Gynecol. 2017;129:e134–e141.
Davenport ML. Approach to the patient with turner syndrome. J Clin Endocrinol Metab. 2010;95(4):1487–1495.
De la Chesnayae E, Canto P, Ulloa-Aguirre A et al. No evidence of mutations in the follicle-stimulating hormone receptor gene in Mexican women with 46,XX pure gonadal dysgenesis. Am J Med Genet. 2001;98:125–128.
De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;376:911–918.
Doherty E, Pakarinen P, Tiitinen A et al. A novel mutation in the FSH receptor inhibiting signal transduction and causing primary ovarian failure. J Clin Endocrinol Metab. 2002;87:1151–1155.
Pouresmaeili F, Fazeli Z et al. Premature ovarian failure: a critical condition in the reproductive potential with various genetic causes. Int J Fertil Steril. 2014;8(1):1–12.
Gicquel C, Gaston V, Cabrol S et al. Assessment of Turner syndrome by molecular analysis of the X chromosome in growth-retarded females. J Clin Endocrinol Metab. 1998;83:1472–1476.
Gordon CM, Ackerman KE, Berga SL et al. Functional hypothalamic amenorrhea: an endocrine society clinic practice guideline. J Clin Endocrinol Metab. 2017;102(5):1413–1439.
Gravholt CH, Fedder J, Naeraa RW et al. Occurrence of gonadoblastoma in females with Turner syndrome and Y chromosome material: a population study. J Clin Endocrinol Metab. 2000;85:3199–3202.
Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev. 1997;18:107–134.
Iezzoni JC, Kap-Herr CV, Golden W et al. Gonadoblastomas in 45,X/46,XY mosaicism. Am J Clin Pathol. 1997;108:197–203.
Lin AE, Lippe B, Rosenfeld RD. Further delineation of aortic dilation, dissection, and rupture in patients with Turner syndrome. Pediatrics. 1998;102:e12.
Lourenco D, Brauner R, Lin L et al. Mutations in NRSA1 associated with ovarian insufficiency. N Engl J Med. 2009;360:1200–1210.
Mazzanti L, Cacciari E, Bergamaschi R et al. Pelvic ultrasonography in patients with turner syndrome: age-related findings in different karyotypes. J Pediatr. 1997;131:135–140.
Melner MH, Feltus FA. Autoimmune premature ovarian failure — endocrine aspects of a t-cell disease: review. Endocrinology. 1999;140:3401–3403.
Nelson LM. Primary ovarian insufficiency. N Engl J Med. 2009;360:606–614.
Pasquino AM, Passeri F, Pucarelli I et al. Spontaneous pubertal development in Turner syndrome. J Clin Endocrinol Metab. 1997;82:1810–1813.
Patwardham AJ, Brown WE, Bender BG et al. Reduced size of the amygdala in individuals with 47,XXY and 47,XXX karyotypes. Am J Med Genet. 2002;114:93–98.
Quigley CA, Crowe BJ, Anglin DG et al. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab. 2002;87:2033–2041.
Rongen-Westerlaken C, Corel K, van den Broeck J et al. Reference values for height, height velocity and weight in Turner syndrome. Acta Paediatr. 1997;86:937–942.
Rosenfeld R, Devine N, Julius Hunold J et al. Treatment of females with Turner syndrome (TS) with very low doses of estrogen beginning at 12 years enhances the growth-promoting effect of GH. J Clin Endocrinol Metab. 2005;90:6424–6430.
Ross JL, Roeltgen D, Feuillan P et al. Use of estrogen in young females with Turner syndrome. Neurology. 2000;54:164–170.
Seashore MR, Cho S, Desposito F et al. American Academy of Pediatrics Committee on Genetics: health supervision for children with Turner syndrome. Pediatrics. 1995;96:1166–1173.
Silva CA, Yamakami LYS, Aikawa NE et al. Autoimmune primary ovarian insufficiency. Autoimmun Rev. 2014;13:427–430.
Sybert VP. Cardiovascular malformations and complications in Turner syndrome. Pediatrics. 1998;101:E11.
Kanasakoski J, Fagerholm R, Laitinen EM et al. Mutation screening of SEMA3A and SEMA7A in patients with congenital hypogonadotropic hypogonadism. Pediatr Res. 2014;75:641–644.
Murphy KG. Kisspeptins: regulators of metastasis and the hypothalamic-pituitarygonadal axis. J Neuroendocrinol. 2005;17:519–525.
Topaloglu AK, Reimann F, Guclu M et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for neurokinin B in the central control of reproduction. Nat Genet. 2009;41:354–358.
Topaloglu AK, Tello JA, Kotan D et al. Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med. 2012;366:629–634.
Tsai P-S, Gill JC. Mechanisms of disease: insights into X-linked and autosomal-dominant kallman syndrome. Nat Clin Pract Endocrinol Metab. 2008;2:160.
Anttonen M, Unkila-Kallio L, Leminen A, et al: High GATA-4 expression associates with aggressive behavior, whereas low anti-M?llerian hormone expression associates with growth potential of ovarian granulosa cell tumors, J Clin Endocrinol Metab 90:6529–6535, 2005.
Cass DL, Hawkins E, Brandt ML, et al: Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period, J Pediatr Surg 36:693–699, 2001.
Fotiou SK: Ovarian malignancies in adolescence, Ann N Y Acad Sci 816:338–346, 1997.
Kalfa N, Ecochard A, Patte C, et al: Activating mutations of the stimulatory G protein in juvenile ovarian granulosa cell tumors: a new prognostic factor?, J Clin Endocrinol Metab 91:1842–1847, 2006.
Lazar EL, Stolar CJ: Evaluation and management of pediatric solid ovarian tumors, Semin Pediatr Surg 7:29–34, 1998. Powell JL, Connor GP, Henderson GS: Management of recurrent juvenile granulosa cell tumor of the ovary, Gynecol Oncol 81:113–116, 2001.
Stepanian M, Cohn D: Gynecologic malignancies in adolescents, Adolesc Med 15:549–568, 2004.
Diamond DA. The ethics of gender in pediatric reconstructive urology. J Urol. 2016;196:305–307.
Rodriguez-Buritica D. Overview of genetics of disorders of sexual development. Curr Opin Pediatr. 2015;27:675–684.
Viau-Colindres J, Axelrad M, Karaviti L et al. Bringing back the term “intersex”. Pediatrics. 2017;140(5):e20170505.
Auchus RJ, Chang AY. 46,XX DSD: the masculinised female. Best Pract Res Clin Endocrinol Metab. 2010;24:219–242.
Bashamboo A, Donohoue PA, Vilain E et al. A recurrent p.Arg92Trp variant in steroidogenic factor 1 (NR5A1) can act as a molecular switch in human sex development. Hum Mol Genet. 2016;25:3446–3453.
Diamond DA, Mitchell C, Lamb K et al. Sex assignment for newborns with ambiguous genitalia and exposure to fetal testosterone: attitudes and practices of pediatric urologists. J Pediatr. 2006;148:445–449.
Diamond M, Sigmundson K. Sex reassignment at birth. Arch Pediatr Adolesc Med. 1997;151:298–304.
Lourenco D, Brauner R, Lin L et al. Mutations in NRA5A1 associated with ovarian insufficiency. N Engl J Med. 2009;360:1200–1210.
Mendonca BB, Leite MV, DeCastro M et al. Female pseudohermaphroditism caused by a novel homozygous mutation of the GR gene. J Clin Endocrinol Metab. 2002;87:1805–1809.
Parisi MA, Ramsdell LA, Burns MW et al. A gender assessment team: experience with 250 patients over a period of 25 years. Genet Med. 2007;9:348–357.
Piferrer F. Epigenetics of sex determination and gonadogenesis. Dev Dyn. 2013;242:360–370.
Romao RLP, Salle JLP, Wherrett DK. Update on the management of disorders of sex development. Pediatr Clin North Am. 2012;59:853–869.
Saenger P. New developments in congenital lipoid adrenal hyperplasia and steroidogenic acute regulatory protein. Pediatr Clin North Am. 1997;44:397–421.
Baxter RM, Arboleda VA, Lee H et al. Exome sequencing for the diagnosis of 46,XY disorders of sex development. J Clin Endocrinol Metab. 2015;100:E333–E344.
Chu J, Zhang R, Zhao Z et al. Male fertility is compatible with an Arg840 Cys substitution in the AR in a large Chinese family affected with divergent phenotypes of AR insensitivity syndrome. J Clin Endocrinol Metab. 2002;87:347–351.
Coutant R, Mallet D, Lahlou N et al. Heterozygous mutation of steroidogenic factor-1 and 46,XY subjects may mimic partial androgen insensitivity syndrome. J Clin Endocrinol Metab. 2007;92:2868–2873.
Diamond DA, Mitchell C, Lamb K et al. Sex assignment for newborns with ambiguous genitalia and exposure to fetal testosterone: attitudes and practices of pediatric urologists. J Pediatr. 2006;148:445–449.
Diamond M, Sigmundson K. Sex reassignment at birth. Arch Pediatr Adolesc Med. 1997;151:298–304.
El-Khairi R, Achermann JC. Steroidogenic factor-1 and human disease. Semin Reprod Med. 2012;30:374–381.
Fluck CE, Meyer-Boni M, Pandley AV et al. Why males will be males: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. The American Journal of Human Genetics. 2011;89:201–218.
Geissler WM, Davis DL, Wu L et al. Male pseudohermaphroditism caused by mutation of testicular 17?-hydroxysteroid dehydrogenase 3. Nat Genet. 1994;7:34–39.
Gul D. Third case of WAGR syndrome with severe obesity and constitutional deletion of chromosome (11)(p12p14). Am J Med Genet. 2002;107:70–71.
Hughes IA, Davies JD, Bunch TI et al. Androgen insensitivity syndrome. Lancet. 2012;380:1419–1428.
Kossack N, Simoni M, Richter-Unruh A et al. Mutations in a novel, cryptic exon of the luteinizing hormone/chorionic gonadotropin receptor gene cause male pseudohermaphroditism. PLoS Med. 2008;5:e88.
McPherson EW, Clemens MM, Gibbons RJ et al. X-linked ?-thalassemia/mental retardation (ATR-X) syndrome: a new kindred with severe genital anomalies and mild hematologic expression. Am J Med Genet. 1995;55:302–306.
Meier M, Moller G, Adamski J. Perspectives in understanding the role of 17?-hydroxysteroid dehydrogenases in health and disease. Ann N Y Acad Sci. 2009;1155:15–24.
Mendonca BB, Inacio M, Costa EMF et al. Male pseudohermaphroditism due to steroid 5?-reductase 2 deficiency. Medicine (Baltimore). 1996;75:64–76.
Moisan AM, Ricketts ML, Tardy V et al. New insight into the molecular basis of 3?-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3 gene in eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. J Clin Endocrinol Metab. 1999;84:4410–4425.
Mongan NP, Jaaskelainen J, Green K et al. Two de novo mutations in the AR gene cause the complete androgen insensitivity syndrome in a pair of monozygotic twins. J Clin Endocrinol Metab. 2002;87:1057–1061.
Parisi MA, Ramsdell LA, Burns MW et al. A gender assessment team: experience with 250 patients over a period of 25 years. Genet Med. 2007;9:348–357.
Quigley CA, French FS. Androgen insensitivity syndromes. Curr Ther Endocrinol Metab. 1994;5:342–351.
Saenger P. New developments in congenital lipoid adrenal hyperplasia and steroidogenic acute regulatory protein. Pediatr Clin North Am. 1997;44:397–421.
Sarafoglou K, Ostrer H. Clinical review 111 — familial sex reversal: a review. J Clin Endocrinol Metab. 2000;85:483–493.
Wallien MS, Cohen-Kettenis PT. Psychosexual outcome of gender-dysphoric children. J Am Acad Child Adolesc Psychiatry. 2008;47:1413–1423.
Berenbaum SA, Bryk KK, Duck SC et al. Psychological adjustment in children and adults with congenital adrenal hyperplasia. J Pediatr. 2004;144:741–746.
Cameron FJ, Montalto J, Byrt E et al. Gonadal dysgenesis: associations between clinical features and sex of rearing. Endocr J. 1997;44:95–104.
Creighton S, Minto C. Managing intersex. Br Med J. 2001;323:1264–1265.
Daaboul J, Frader J. Ethics and the management of the patient with intersex: a middle way. J Pediatr Endocrinol Metab. 2001;14:1575–1583.
Diamond DA, Mitchell C, Lamb K et al. Sex assignment for newborns with ambiguous genitalia and exposure to fetal testosterone: attitudes and practices of pediatric urologists. J Pediatr. 2006;148:445–449.
Fagerholm R, Santtila P, Miettinen PJ et al. Sexual function and attitudes toward surgery after feminizing genitoplasty. J Urology. 185:1900–1904, 2011.
Frade Costa EM, Bilharinho Mendonca B, Inacio M et al. Management of ambiguous genitalia in pseudohermaphrodites: new perspectives on vaginal dilation. Fertil Steril. 1997;67:229–232.
Houk CP, Hughes IA, Ahmed SF et al. Summary of consensus statement on intersex disorders and their management. Pediatrics. 2006;118:753–757.
Lee PA, Houk CP, Ahmed SF et al. Consensus statement on management of intersex disorders. Pediatrics. 2006;118:e488–e500.
Looijenga LHJ, Hersmus R, LeLeeuw BHCGM et al. Gonadal tumours and DSD. Best Pract Res Clin Endocrinol Metab. 2010;24:291–310.
MacLaughlin DT, Donahoe PK. Sex determination and differentiation. N Engl J Med. 2004;350:367–378.
Parisi MA, Ramsdell LA, Burns MW et al. A gender assessment team: experience with 250 patients over a period of 25 years. Genet Med. 2007;9:348–357.
Wisniewski AB. Gender development in 46,XY DSD: Influences of nature and nurture. Scientifica, Article ID 834967, 2012.
Achenbach P, Hummel M, Th?mer L, et al: Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children, Diabetologia 56:1615–1622, 2013.
Ali K, Harnden A, Edge JA: Type 1 diabetes in children, BMJ 342: d294, 2011.
American Diabetes Assocition: Children and adolescents, Diabetes Care 39(Suppl 1): S86–S93, 2016.
American Diabetes Association: Diagnosis and classification of diabetes mellitus, Diabetes Care 37(Suppl 1): S81–S90, 2014.
American Diabetes Association: Standards of medical care in diabetes — 2017, Diabetes Care 40(Suppl 1): S1–S135, 2017.
Atkinson MA, Eisenbarth GS, Michels AW: Type 1 diabetes, Lancet 383:69–78, 2014.Bach JF: Anti-CD3 antibodies for type 1 diabetes: beyond expectations, Lancet 378:459–460, 2011.
Bach JF, Chatenoud L: The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes, Cold Spring Harb Perspect Med 2(2): a007799, 2012.
Bergenstal RM, Gal RL, Connor CG, et al: Racial differences in the relationship glucose concentrations and hemoglobin A1c levels, Ann Intern Med 167(2):95–102, 2017.
Boerner BP, Sarvetnick NE: Type 1 diabetes: role of intestinal microbiome in humans and mice, Ann NY Acad Sci 1243:103–118, 2011.
Bonifacio E: Targeting innate immunity in type 1 diabetes: strike one, Lancet 381:1880–1881, 2013.
Cardwell CR, Carson DJ, Patterson CC: No association between routinely recorded infections in early life and subsequent risk of childhood-onset type 1 diabetes: a matched case-control study using the UK General Practice Research Database, Diabet Med 25:261–267, 2008.
Choudhary P: Insulin pump therapy with automated insulin suspension: toward freedom from nocturnal hypoglycemia, JAMA 310:1235–1236, 2013.
Concannon P, Rich SS, Nepom GT: Genetics of type 1A diabetes, N Engl J Med 360:1646–1654, 2009.
Dabelea D: The accelerating epidemic of childhood diabetes, Lancet 373:1999–2000, 2009.
Dabelea D, Bell RA, D’Agostino RB Jr, et al: Incidence of diabetes in youth in the United States, JAMA 297:2716–2724, 2007.
Dunger DB, Todd JA: Prevention of type 1 diabetes: what next? Lancet 372:1710–1711, 2008
Frohlich-Reiterer EE, Kaspers S, Hofer S, et al: Anthropometry, metabolic control, and follow-up in children and adolescents with type 1 diabetes mellitus and biopsy-proven celiac disease, J Pediatr 158:589–593, 2011.
Frederiksen B, Kroehl M, Lamb M, et al: Infant exposures and development of Type 1 diabetes mellitus: The Diabetes Autoimmunity Study in the Young (DAISY), JAMA Pediatr 167(9):808–815, 2013.
Graves PM, Barriga KJ, Norris JM, et al: Lack of association between early childhood immunizations and beta-cell autoimmunity, Diabetes Care 22:1694–1697, 1999.
Groop L: Open chromatin and diabetes risk, Nat Genet 42:190–192, 2010.Hagopian W, Lee HS, Liu E, et al: Co-occurrence of type 1 diabetes and celiac disease autoimmunity, Pediatrics 149(5): e20171305, 2017.
Hober D, Same F: Enteroviruses and type 1 diabetes, BMJ 341:c7072, 2010.
Hoppu S, Ronkainen MS, Kimpim?ki T, et al: Insulin autoantibody isotypes during the prediabetic process in young children with increased genetic risk of type I diabetes, Pediatr Res 55:236–242, 2004.
Hummel K, McFann KK, Realsen J, et al: The increasing onset of type 1 diabetes in children, J Pediatr 161:652–657, 2012.
Hummel SP, Fluger M, Hummel M, et al: Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes, Diabetes Care 34:1301–1305, 2011.
Ierodiakonou D, Garcia-Larsen V, Logan A, et al: Timing of allergenic food introduction to the infant diet and risk of allergic or autoimmune disease, JAMA 316(11):1181–1192, 2016.
Imperatore G, Boyle JP, Thompson TJ, et al, SEARCH for Diabetes in Youth Study Group: Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth, Diabetes Care 35:2515–2520, 2012.
Insel RA, et al: Staging Presymptomatic Type 1 Diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association, Diabetes Care 38(10):1964–1974, 2015
Karavanaki K, Tsoka E, Liacopoulou M, et al: Psychological stress as a factor potentially contributing to the pathogenesis of Type 1 diabetes mellitus, J Endocrinol Invest 31:406–415, 2008.
Kemppainen KM, Ardissone AN, Davis-Richardson AG, et al, The TEDDY Study Group: Early childhood gut microbiomes show strong geographic differences among subjects at high risk for type 1 diabetes, Diabetes Care 38(2):329–332, 2015.
Knip M, Akerblom HK, Becker D, et al: Hydrolyzed infant formula and early ?-cell autoimmunity a randomized clinical trial, JAMA 311:2279–2286, 2014.
Krischer JP, Lynch KF, Schatz DA, et al, TEDDY Study Group: The 6-year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study, Diabetologia 58(5):980–987, 2015.
Kurppa K, Laitinen A, Agardh D: Coeliac disease in children with type 1 diabetes, Lancet 2:133–142, 2018.
Lima BS, Ghaedi H, Daftarian N, et al: c.376G>A mutation in WFS1 gene causes Wolfram syndrome without deafness, Eur J Med Genetics 59:65–69, 2016.
Mathieu C, Gillard P: Arresting type 1 diabetes after diagnosis: GAD is not enough, Lancet 378:291–292, 2011.
Livingstone SJ, Levin D, Looker HC, et al: Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010, JAMA 313(1):37–44, 2014.
Mayer-Davis EJ, Lawrence JM, Dabelea D, et al: Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012, N Engl J Med 376(15):1419–1429, 2017.
Mohr SB, Garland CF, Gorham ED, et al: The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide, Diabetologia 51:1391–1398, 2008.
Mortensen HB, Hougaard P, Swift P, et al: new definition for the partial remission period in children and adolescents with type 1 diabetes, Diabetes Care 32:1384–1390, 2009.
Nanto-Salonen K, Kupila A, Simell S, et al: Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomized controlled trial, Lancet 372:1746–1755, 2008.
Nejentsev S, Howson JM, Walker NM, et al: Wellcome Trust Case Control Consortium, Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A, Nature 450:887–892, 2007.
Oron T, Gat-Yablonski G, Lazar L, et al: Stress hyperglycemia: a sign of familial diabetes in children, Pediatrics 128: e1614–e1617, 2011.
Patterson CC, Dahlquist GG, Gyurus E, et al: Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study, Lancet 373:2027–2033, 2009.
Quinn M, Fleishman A, Rosner B, et al: Characteristics at diagnosis of type 1 diabetes in children younger than 6 years, J Pediatr 148:366–371, 2006.
Redondo MJ, Jeffrey J, Fain PR, et al: Concordance for islet autoimmunity among monozygotic twins, N Engl J Med 359:2849–2850, 2008.
Richardson SJ, Willcox A, Bone AJ, et al: The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes, Diabetologia 52:1143–1151, 2009.
Roep BO: New hope for immune intervention therapy in type 1 diabetes, Lancet 378:376–378, 2011.
Sadauskaite-Kuehne V, Ludvigsson J, Padaiga Z, et al: longer breastfeeding is an independent protective factor against development of type 1 diabetes mellitus in childhood, Diabetes Metab Res Rev 20:150–157, 2004.
Selvin E, Steffes MW, Gregg E, et al: Performance of A1c for the classification and prediction of diabetes, Diabetes Care 34(1):84–89, 2011.
Smyth DJ, Plagnol V, Walker NM, et al: Shared and distinct genetic variants in type 1 diabetes and celiac disease, N Engl J Med 359:2767–2776, 2008.
Tuomi T, Santoro N, Caprio S, et al: The many faces of diabetes: a disease with increasing heterogeneity, Lancet 383:1084–1092, 2014.
Vaarala O: Human intestinal microbiota and type 1 diabetes, Curr Diab Rep 13:601–607, 2013.
Wherrett DK, Bundy B, Becker DJ, et al: Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomized double-blind trial, Lancet 378:319–326, 2011.
Whincup PH, Kaye SJ, Owen CG, et al: Birth weight and risk of type 2 diabetes: a systematic review, JAMA 300:2886–2897, 2008.
Writing Group for the TRIGR Study Group: Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes — The TRIGR randomized clinical trial, JAMA 319(1):38–48, 2018.
Writing Group for the TRIGR Study Group: Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes — a randomized clinical trial, JAMA 318(19):1891–1902, 2017.
Yeung WC, Rawlinson WD, Craig ME: Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies, BMJ 342: d35, 2011.
Ziegler AG, Rewers M, Simell O, et al: Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children, JAMA 309:2473–2479, 2013.
Zipitis CS, Akobeng AK: Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis, Arch Dis Child 93:512–517, 2008.
Aly TA, Ide A, Jahromi MM, et al: Extreme genetic risk for type 1A diabetes, Proc Natl Acad Sci USA 103:14074–14079, 2006.
Gillespie K, Bain SC, Barnett AH, et al: The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes, Lancet 364:1699–1700, 2004.
Gullstrand C, Wahlberg J, Ilonen J, et al: Progression to type 1 diabetes and autoantibody positivity in relation to HLA-risk genotypes in children participating in the ABIS study, Pediatr Diabetes 9(3 Pt 1):182–190, 2008.
Mayer-Davis EJ, Bell RA, Dabelea D, et al: The many faces of diabetes in American youth: type 1 and type 2 diabetes in five race and ethnic populations: the SEARCH for Diabetes in Youth Study, Diabetes Care 32(Suppl 2): S99–S101, 2009.
Oram RA, Patel K, Hill A, et al: A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults, Diabetes Care 39:337–344, 2016.
Pociot F, Lernmark A: Genetic risk factors for type 1 diabetes, Lancet 387:2331–2339, 2016.
Siljander HT, Veijola R, Reunanen A, et al: Prediction of type 1 diabetes among siblings of affected children and in the general population, Diabetologia 50:2272–2275, 2007.
Stankov K, Benc D, Draskovic D: Genetic and epigenetic factors in etiology of diabetes mellitus type 1, Pediatrics 132:1112–1122, 2013.
Dabelea D, Rewers A, Stafford JM, et al: Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study, Pediatrics 133: e938–e945, 2014.
Dunger DB, Sperling MA, Acerini CL, et al: European Society for Pediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society consensus statement on diabetic ketoacidosis in children and adolescents, Pediatrics 113: e133–e140, 2004.
Edge JA, Jakes RW, Roy Y, et al: The UK case-control study of cerebral edema complicating diabetic ketoacidosis in children, Diabetologia 49:2002–2009, 2006.
Fiordalisi I, Novotny WE, Holbert D, et al, Critical Care Management Group: An 18-yr prospective study of pediatric diabetic ketoacidosis: an approach to minimizing the risk of brain herniation during treatment, Pediatr Diabetes 8:142–149, 2007.
Glaser NS, Wootton-Gorges SL, Buonocore MH, et al: Subclinical cerebral edema in children with diabetic ketoacidosis randomized to 2 different rehydration protocols, J Pediatr 131: e73–e80, 2013.
Glaser NS, Wootton-Gorges SL, Marcin JP, et al: Mechanism of cerebral edema in children with diabetic ketoacidosis, J Pediatr 145:164–171, 2004.
Hom J, Sinert R: Evidence-based emergency medicine/critically appraised topic. Is fluid therapy associated with cerebral edema in children with diabetic ketoacidosis? Ann Emerg Med 52:69–75, 2008.
Kamel KS, Halperin ML: Acid-base problems in diabetic ketoacidosis, N Engl J Med 372(6):546–554, 2015.
Karges B, Schwandt A, Heidtmann B, et al: Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes, JAMA 318(14):1358–1366, 2017.
Klingensmith GJ, Tamborlane WV, Wood J, et al: Diabetic ketoacidosis at diabetes onset: still an all-too-common threat in youth, J Pediatr 162:330–334, 2013.
Kuppermann N, Ghetti S, Schunk JE, et al: Clinical trial of fluid infusion rates for pediatric diabetic ketoacidosis, N Engl J Med 378(24):2275–2287, 2018.
Lawrence SE, Cummings EA, Gaboury I, et al: Population-based study of incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis, J Pediatr 146:688–692, 2005.
Muir AB, Quisling RG, Yang MCK, et al: Cerebral edema in childhood diabetic ketoacidosis: natural history, radiographic findings, and early identification, Diabetes Care 27:1541–1546, 2004.
Rosenbloom AL: The management of diabetic ketoacidosis in children, Diabetes Ther 1(2):103–120, 2010.
Veverka M, Marsh K, Norman S, et al: A pediatric diabetic ketoacidosis management protocol incorporating a two-bag intravenous fluid system decreases duration of intravenous insulin therapy, J Pediatr Pharmacol Ther 21(6):512–517, 2016.
Yadav D, Nair S, Norkus EP, Pitchumoni CS: Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities, Am J Gastroenterol 95(11):3123–3128, 2000.
Zeitler P, Haqq A, Rosenbloom A, et al: Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment, J Pediatr 158(1):9–14, 2011.
Alemzadeh R, Berhe T, Wyatt DT: Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus, Pediatrics 115:1320–1324, 2005.
Alemzadeh R, Palma-Sisto P, Holzum MK, et al: Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus, Diabetes Technol Ther 9:339–347, 2007.
Bergenstal RM, Klonoff DC, Garg SK, et al: Threshold-based insulin-pump interruption for reduction of hypoglycemia, N Engl J Med 369:224–232, 2013.
Cameron FJ, Wherrett DK: Care of diabetes in children and adolescents: controversies, changes, and consensus, Lancet 385:2096–2104, 2015.
Chase HP, Lutz K, Pencek R, et al: Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study, J Pediatr 155:369–373, 2009.
Chiang JL, Kirkman MS, Laffel LMB, et al: Type 1diabetes through the life span: a position statement of the American Diabetes Association, Diabetes Care 37:2034–2054, 2014.
de Kort H, de Koning EJ, Rabelink TJ, et al: Islet transplantation in type 1 diabetes, BMJ 342: d217, 2011.
Donaghue KC, Wadwa RP, Dimeglio LA, et al: Microvascular and macrovascular complications in children and adolescents, Pediatr Diabetes 15(Suppl 20):257–269, 2014.
Farmer A: Use of HbA1C in the diagnosis of diabetes, BMJ 345: e7293, 2012.
El-Khatib F, Balliro C, Hillard MA, et al: Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicenter randomized crossover trial, Lancet 389:369–380, 2017.
Forlenza GP, Buckingham B, Maahs DM: Progress in diabetes technology: developments in insulin pumps, continuous glucose monitor, and progress towards the artificial pancreas, J Pediatr 169:13–20, 2016.
Garg SK, Weinzimer SA, Tamborlane WV, et al: Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes, Diabetes Technol Ther epub ahead of print, 2017.
Kapellen TM, Heidtmann B, Lilienthal E, et al: Continuous subcutaneous insulin infusion in neonates and infants below 1 year: analysis of initial bolus and basal rate based on the experiences from the German Working Group for Pediatric Pump Treatment, Diabetes Technol Ther 17(12):872–879, 2015.
Lane W, Bailey TS, Gerety G, et al: Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes—The SWITCH 1 randomized clinical trial, JAMA 318(1):33–44, 2017.
Lennerz BS, Barton A, Bernstein RK, et al: Management of type 1 diabetes with a very low carbohydrate diet, Pediatrics 141(6): e20173349, 2018.
Libman IM, Miller KM, DiMeglio LA, et al; for the T1D Exchange Clinical Network Metformin RCT Study Group: Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes, JAMA 314(21):2241–2250, 2015.
Ly TT, Nicholas JA, Retterath A, et al: Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes—a randomized clinical trial, JAMA 310:1240–1246, 2013
The Medical Letter: Insulin degludec/liraglutide (xultophy 100/3.6) for type 2 diabetes, Med Lett 59(1529):147–150, 2017.
The Medical Letter: MiniMed 530G: an insulin pump with low-glucose suspend automation, Med Lett Drugs Ther 55:97–98, 2013.
The Medical Letter: Minimed 67OG: a hybrid closed-loop insulin delivery system, Med Lett 58(1508):147–148, 2016.
Okawa T, Tsunekawa S, Seino Y, et al: Deceptive HbA1c in a patient with pure red cell aplasia, Lancet 382:366–367, 2013.
Phillip M, Battelino T, Atlas E, et al: Nocturnal glucose control with an artificial pancreas at a diabetes camp, N Engl J Med 368:824–832, 2013.
Raman VS, Heptulla RA: New potential adjuncts to treatment of children with type 1 diabetes mellitus, Pediatr Res 65:370–374, 2009.
Regan FM, Dunger DB: Use of new insulins in children, Arch Dis Child 91: ep47–ep53, 2006.
Runge C, Lee JM: How low can you go? Does lower carb translate to lower glucose? Pediatrics 141(6): e20180957, 2018.
Russell SJ, El-Khatib FH, Sinha M, et al: Outpatient glycemic control with a bionic pancreas in type 1 diabetes, N Engl J Med 371:313–324, 2014.
Smart CE, Annan F, Bruno LPC, et al: Nutritional management in children and adolescents with diabetes, Pediatr Diabetes 15(Suppl 20):135–153, 2014.
Staeva TP, Chatenoud L, Insel R, et al: Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials, Diabetes 62:9–17, 2013.
Taplin CE, Cobry E, Messer L, et al: Preventing post-exercise nocturnal hypoglycemia in children with type 1 diabetes, J Pediatr 157:784–788, 2010.
Turksoy K, Frantz N, Quinn L, et al: Automated insulin delivery — the light at the end of the tunnel, J Pediatr 186:17–28, 2017.
Voltarelli JC, Couri CE, Stracieri AB, et al: Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus, JAMA 297:1568–1576, 2007.
Weinzimer S, Ahern JH, Doyle EA, et al: Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report, Pediatrics 114:1601–1605, 2004.
Zeitler P, Haqq A, Rosenbloom A, et al: Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment, J Pediatr 158:9–14, 2011.
American Diabetes Association: Standards of medical care in Diabetes—2017, Diabetes Care 40(Suppl 1):2017.
Cleary PA, Orchard TJ, Genuth S, et al: The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study, Diabetes 55:3556–3565, 2006.
Gaudieri PA, Chen R, Greer TF, et al: Cognitive function in children with type 1 diabetes: a meta-analysis, Diabetes Care 31:1892–1897, 2008.
Grey M, Whittemore R, Tamborlane W: Depression in type 1 diabetes in children: natural history and correlates, J Psychosom Res 53:907–911, 2002.
Hough FS, Pierroz DD, Cooper C, et al: Mechanisms and evaluation of bone fragility in type 1 diabetes, Eur J Endocrinol 174(4):127–138, 2016.
Jaiswal M, Lauer A, Martine CL, et al: Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow up cohort, Diabetes Care 36:3903–3908, 2013.
Rosenbloom AL: Limited joint mobility in childhood diabetes: discovery, description, and decline, J Clin Endocrinol Metab 98:466–473, 2013.
Standl E, Owen DR: New long-acting basal insulins: does benefit outweigh cost? Diabetes Care 39(Suppl 2): S172–S179, 2016.
Vestergaard P: Discrepancies in bone mineral density and fracture risk in patients with type1 and type 2 diabetes—a meta-analysis, Osteoporosis Int 18:427–444, 2007.
Wang PH: Tight glucose control and diabetic complications, Lancet 342:129, 1993.
Weber DR, Haynes K, Leonard MB, et al: Type 1 diabetes is associated with an increased fracture risk across the lifespan: a population-based cohort study using The Health Improvement Network (THIN), Diabetes Care 38(10):1913–1920, 2015.
White NH: Long-term outcomes in youth with diabetes mellitus, Pediatr Clin North Am 62(4):889–909, 2015.
Yau J, Rogers SL, Kawasaki R, et al: Global prevalence and major risk factors of diabetic retinopathy, Diabetes Care 35(3):556–564, 2012.
Young-Hyman D, de Groot M, Hill-Briggs F, et al: Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care 39(12):2126–2140, 2016.
Azoulay L, Yin H, Filion KB, et al: The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study, BMJ 344: e3645, 2012.
Beck SE, Marcus CL: Pediatric polysomnography, Sleep Med Clin 4(3):393–406, 2009.
Chiefari E, Tanyolac S, Paonessa F, et al: Functional variants of the HMGA1 gene and type 2 diabetes mellitus, JAMA 305(9):903–912, 2011.
Copeland KC, Silverstein J, Moore KR, et al: Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents, Pediatrics 131:364–382, 2013.
Currie CJ, Peters JR, Tynan A, et al: Survival as a function of HbA1C in people with type 2 diabetes: a retrospective cohort study, Lancet 375:481–488, 2010.
Diamant M, Morsink LM: SGLT2 inhibitors for diabetes: turning symptoms into therapy, Lancet 382:917–918, 2013.
Dixon JB, le Roux CW, Rubino F, et al: Bariatric surgery for type 2 diabetes, Lancet 379:2300–2308, 2012.
Fennoy I: ?-Cell dysfunction and the onset of type 2 diabetes, J Pediatr 160:895–896, 2012.
Fuchsberger C, Flannick J, Teslovich TM, et al: The genetic architecture of type 2 diabetes, Nature 536(7614):41–47, 2016.
Gale E: Incretin therapy: should adverse consequences have been anticipated? BMJ 346: F3617, 2013.
Gale EAM: GLP-1 based agents and acute pancreatitis, BMJ 346:9, 2013.
Hamman RF, Bell RA, Dabelea D, et al, SEARCH for diabetes in youth Study Group: The SEARCH for Diabetes in Youth Study: rationale, findings, and future directions, Diabetes Care 37(12):3336–3344, 2014.
Idris I, Warren G, Donnelly R: Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes, Arch Intern Med 172:1005–1011, 2012.
Incretin Safety Study Investigators: Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies, BMJ 348: g2366, 2014.
Kahn SE, Cooper ME, Del Prato S: Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future, Lancet 383:1068–1078, 2014.
Krook A, Brueton L, O’Rahilly S: Homozygous nonsense mutation in the insulin receptor gene in an infant with leprechaunism, Lancet 342:277–278, 1993.
Langenberg C, Lotta LA: Genomic insights into the causes of type 2 diabetes, Lancet 391:2463–2474, 2018.
Lasserson D, Mant J: The role of dipeptidyl peptidase-4 inhibitors, BMJ 344: e1213, 2012.
The Medical Letter: Drugs for type 2 diabetes, Med Lett 59(1512):9–18, 2017.
McCarthy MI: Genomics, type 2 diabetes, and obesity, N Engl J Med 363(24):2339–2350, 2010.
Meehan C, Silverstein J: Treatment options for type 2 diabetes in youth remain limited, J Pediatr 170:20–27, 2016.
Nadeau JK, Anderson BJ, Berg EG, et al: Youth-Onset Type 2 Diabetes Consensus Report: current status, challenges, and priorities, Diabetes Care 39(9):1635–1642, 2016.
Nguyen QM, Srinivasan SR, Xu JH, et al: Fasting plasma glucose levels within the normoglycemic range in childhood as a predictor of prediabetics and type 2 diabetes in adulthood, Arch Pediatr Adolesc Med 164:124–128, 2010.Schauer PR, Bhatt DL, Kirwin JP, et al: Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes, N Engl J Med 376(7):641–650, 2017.
Styne DM, Arslanian SA, Conner EL, et al: Pediatric obesity—assessment, treatment, and prevention: an endocrine society clinical practice guideline, JCEM 102(3):709–757, 2017.
Talmud PJ, Hingorani AD, Cooper JA, et al: Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study, BMJ 340:192, 2010.
The Healthy Study Group: A school-based intervention for diabetes risk prevention, N Engl J Med 363(5):443–452, 2010.
The SIGMA Type 2 Diabetes Consortium: Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population, JAMA 311:2305–2314, 2014.
TODAY Study Group: A clinical trial to maintain glycemic control in youth with type 2 diabetes, N Engl J Med 366:2247–2256, 2012.
Viner R, White B, Christie D: Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden, Lancet 389:2252–2260, 2017.
Voight BF, Scott LJ, Steinthorsdottir V, et al: Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis, Nat Genet 42:579–589, 2010.
Weigensberg MJ, Goran MI: Type 2 diabetes in children and adolescents, Lancet 373:1743–1744, 2009.
Weiss R, Santoro N, Giannini C, et al: Prediabetes in youths: mechanisms and biomarkers, Lancet Child Adolesc 1:240–248, 2017.
Yang W: Diagnosing diabetes using glycated haemoglobin A1c, BMJ 340:c2262, 2010.
Adler AI, Shine BS, Chamnan P, et al: Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults, Diabetes Care 31:1789–1794, 2008.
Constantino MI, Molyneaux L, Limacher-Gisler F, et al: Long-term complications and mortality in young-onset diabetes, Diabetes Care 36:3863–3869, 2013.
Morian A, Brunzell C, Cohen RC, et al; for the CFRD Guidelines Committee: Clinical care guidelines for cystic fibrosis-related diabetes, Diabetes Care 33(12):2697–2708, 2010.
Morrison EY, McKenzie K: The Mauriac syndrome, West Indian Med J 38:180–182, 1989.
Mozzillo E, Franzese A, Valerio G, et al: One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements, Pediatr Diabetes 10:162–167, 2009.
Rigoli L, Di Bella C: Wolfram syndrome 1 and wolfram syndrome 2, Curr Opin Pediatr 24:512–517, 2012.
Semple RK, Savage DB, Halsall DJ, et al: Syndromes of severe insulin resistance and/or lipodystrophy. In Weiss RE, Refetoff S, editors: Genetic diagnosis of endocrine disorders, Philadelphia, 2010, Elsevier/Saunders.
Steele AM, Shields BM, Wensley KJ, et al: Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia, JAMA 311:279–286, 2014.
Thanabalasingham G, Owen KR: Diagnosis and management of maturity onset diabetes of the young (MODY), BMJ 343: d6044, 2011.
Van den Berg JM, Morton AM, Kok SW, et al: Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD), J Cyst Fibros 7:515–519, 2008.
Alcolado JC, Thomas AW: Maternally inherited diabetes mellitus: the role of mitochondrial DNA defects, Diabet Med 12:102–108, 1995.
Babenko AP, Polak M, Cav? H, et al: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus, N Engl J Med 355:456–466, 2006.
Chen R, Hussain K, Al-Ali M, et al: Neonatal and late-onset diabetes mellitus caused by failure of pancreatic development: report of 4 more cases and a review of the literature, Pediatrics 121: e1541–e1547, 2008.
De Franco E, Flanagan SE, Houghton JAL, et al: The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study, Lancet 386:957–963, 2015.
Geffner ME, Clare-Salzler M, Kaufman DL, et al: Permanent diabetes developing after transient neonatal diabetes, Lancet 341:1095, 1993.
Gloyn AL, Pearson ER, Antcliff AF, et al: Activating mutations in the gene encoding the ATP-sensitive potassium channel subunit Kir6.2 and permanent neonatal disease, N Engl J Med 350:1838–1849, 2004.
Metz C, Cav? H, Bertrand AM, et al: Neonatal diabetes mellitus: chromosomal analysis in transient and permanent cases, J Pediatr 141:483–489, 2002.
Pearson ER, Flechtner I, Nj?lstad PR, et al: Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations, N Engl J Med 355:467–477, 2006.
Shield JP: Neonatal diabetes, Horm Res 68(Suppl 5):32–36, 2007.
St?y J, Greeley SA, Paz VP, et al: Diagnosis and treatment of neonatal diabetes: a United States experience, Pediatr Diabetes 9:450–459, 2008.
Turkkahraman D, Bircan I, Tribble ND, et al: Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy, J Pediatr 153:122–126, 2008.
Bolli GB, Fanelli CG: Unawareness of hypoglycemia, N Engl J Med 333:1771–1772, 1995.
Diabetes Control and Complications Trial Research Group: Hypoglycemia in the diabetes control and complications trial, Diabetes 46:271–286, 1997.
Gschwend S, Ryan C, Atchinson J, et al: Effects of acute hyperglycemia on mental efficiency and counterregulatory hormones in adolescents with insulin-dependent diabetes mellitus, J Pediatr 126:178–184, 1995.
McCrimmon RJ, Gold AE, Deary IJ, et al: Symptoms of hypoglycemia in children with IDDM, Diabetes Care 18:858–861, 1995.
Porter PA, Keating B, Byrne G, et al: Incidence and predictive criteria of nocturnal hypoglycemia in young children with insulin-dependent diabetes mellitus, J Pediatr 130:366–372, 1997.
Silverstein JH, Gordon G, Pollock BH, et al: Long-term glycemic control influences the onset of limited joint mobility in type I diabetes, J Pediatr 132:944–947, 1998.
Brennan DC, Kopetskie HA, Sayre PH, et al: Long-term follow-up of the edmonton protocol of islet transplantation in the United States, Am J Transplant 16(2):509–517, 2016.
Couri CEB, Oliveira MCB, Stracieri ABP, et al: C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus, JAMA 301:1573–1579, 2009.
Hering BJ, Kandaswamy R, Ansite JD, et al: Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes, JAMA 293:830–835, 2005.
Kaddis JS, Olack BJ, Sowinski J, et al: Human pancreatic islets and diabetes research, JAMA 301:1580–1587, 2009.
Mitanchez D, Doiron B, Chen R, et al: Glucose-stimulated genes and prospects of gene therapy for type 1 diabetes, Endocr Rev 18:520–540, 1997.
Robertson RP: Islet transplantation as a treatment for diabetes—a work in progress, N Engl J Med 350:694–705, 2004.
Ryan EA, Lakey JR, Paty BW, et al: Successful islet transplantation: continued insulin reserve provides long-term glycemic control, Diabetes 51:2148–2157, 2002.
Shapiro AM, Ricordi C, Hering BJ, et al: International trial of the Edmonton protocol for islet transplantation, N Engl J Med 355:1318–1330, 2006.
